WALL ST

MEDICAL INNOVATION OLYMPICS

ORGANIZED BY AMEDEA PHARMA

#MIO2026

AMEDEA PHARMA

DIAPIN THERAPEUTICS

ENAMEL PURE

FACET DYNAMICS

ADELLE DIAGNOSTICS

CALARIS DIAGNOSTICS

MYCAZED THERAPHEUTICS

PINNACLE TECHNOLOGY PARTNERS (RTP)

PEACCEL

ATHENI

INANNA CERTIFICATIONS

BEST PRACTICES, LLC

ALIRA HEALTH

BIOMEMS

CATCHU

NEW FRONTIER LABS

WALL ST NEW YORK MAGAZINE NYC

WALL ST NEW YORK MAGAZINE

NOVEMBER 15, 2026

ADVERTISEMENT



New to the Street

CEO INTERVIEWS & BILLBOARDS
SINCE 2009

PLEASE E MAIL US TO BOOK
INFO@WALLSTNEWYORKMAGAZINE.COM

WATCH INTERVIEWS

WALL ST



2026 MEDICAL INNOVATION OLYMPICS - FINAL RESULTS

WALL ST NEW YORK MAGAZINE
EDITORIAL BOARD | OCTOBER 16, 2026

The Medical Innovation Olympics 2026, organized by Amedea Pharma and its CEO, Tim Mikhelashvili, brought together an extraordinary international community of healthcare leaders, scientists, entrepreneurs, innovators, investors, and champions united by a common purpose: advancing innovation in medicine.

On behalf of Wall St New York Magazine, we congratulate all of the competitors, finalists, and participants who contributed to this remarkable international forum. We extend our special congratulations to the 2026 Gold Medalists: Jessica Reed of DIAPIN Therapeutics, winner in the PRODUCT category, and Maria Grazia Ruocco of Adelle Diagnostics, winner in the CONCEPT category.

Their achievements represent the innovative spirit and excellence at the heart of the Medical Innovation Olympics.

Other #MIO2026 medals were awarded to Nathan Monty of EnamelPure – Silver, and Chris Sturm - Bronze in the PRODUCT category. In the CONCEPT Category, Jim Chen of Calaris Diagnostics won the Silver medal and David Larwood of MycaZED Therapeutics received the Bronze medal.

The Medical Innovation Olympics is more than a healthcare conference. It is a unique international platform that combines the spirit of athletic competition with the scientific method, creating an environment where innovation, excellence, transparency, and healthy competition can come together.

Under the leadership of Tim Mikhelashvili and Amedea Pharma, the Medical Innovation Olympics has developed a powerful vision: “Building a New Generation of Healthcare Champions.” This vision recognizes that meaningful progress in healthcare requires more than promising ideas. It requires champions—individuals and organizations prepared to challenge established standards, pursue measurable results, embrace new technologies, and create opportunities for innovation to reach the market and ultimately benefit patients.

The 2026 competition demonstrated the strength of this philosophy. The finalists presented innovative approaches to some of healthcare’s most important challenges while engaging with experts, investors, entrepreneurs, and an international audience.

For *Wall St New York Magazine*, this mission is particularly significant. We believe healthcare innovation is one of the most important areas where science, business, investment, entrepreneurship, and global leadership converge. The Medical Innovation Olympics creates a valuable bridge between scientific discovery and the broader business and investment community.

NEW YORK

ADVERTISEMENT



YY Group
NASDAQ: YFOR
OCTOBER 2, 2026

YY FORCE DEPLOYS HOSPITALITY SERVICE ROBOT AT MARRIOTT HOTEL IN MALAYSIA

SafeSpace
OTC: SSGC
SEPTEMBER 29, 2026

SAFESPACE GLOBAL BEGINS PAID AL SAFETY DEPLOYMENT AT TENNESSEE BEHAVIORAL HEALTH FACILITY

NewsOut!

FreeCast
NASDAQ: CAST
SEPTEMBER 29, 2026

FREECAST REPORTS $711K REVENUE AND RAISES $23.7M AS COMMERCIAL ROLLOUT ADVANCES

STARDUST POWER
NASDAQ: DVLT
SEPTEMBER 15, 2026

STARDUST POWER ADVANCES OKLAHOMA LITHIUM REFINERY TOWARD 50,000-TON ANNUAL CAPACITY

AMERICAN FUSION
OTCMKTS: AMFN
SEPTEMBER 29, 2026

AMERICAN FUSION DETAILS TEXATRON TECHNOLOGY DESIGNED TO HARNESS FUSION ENERGY

NewsOut!

TO BOOK A VIDEO PRESS RELEASE
INFO@WALLSTNEWYORKMAGAZINE.COM

WALL ST NEW YORK MAGAZINE



JESSICA REED
DIAPIN

MAIA BARTAIA
CONSUL-GENERAL OF GEORGIA

CHRIS COOK
UK OLYMPIAN

TIM MIKHELASHVILI
AMEDEA PHARMA

WALL ST NEW YORK

AMEDEA PHARMA

BUILDING NEW HEALTHCARE CHAMPIONS

EDITORIAL BOARD | OCTOBER 16, 2026

Powered by Competition & Transparency

In our era of advanced technology, AI and unprecedented competition for resources to drive innovation in healthcare, the spotlights on efficiency and demand for transparency have never been greater than today. Yet at the same time, the brightest minds among scientists and leaders behind medical innovation are driven by new mechanisms, genetic mutations, and the promise of saving or prolonging patients' lives, not by efficiency as they pursue their research relentlessly from failure to failure.

There is an impact health tech company focused on bottom-line business performance analytics in life sciences, Amedea Pharma, that understands this reality and the need for data to inspire. Therefore, its CEO, Tim Mikhelashvili, PhD, and his wife and co-founder, Irina Mikhelashvili, MD, are building a new generation of elite healthcare champions who operate like Olympic teams.

Their team of Commercial, Medical Executives, MIT and Harvard Graduates, and Olympic athletes has discovered an industry-first, practical solution to make transparency and competition for innovation meaningful and exciting so executives can use these powerful forces to their advantage via a practical, centralized software platform called ANCORA Decision Assistant, which generates the real views of the daily contributions and collaborations across the entire organization that are required to drive real results on business and patients, justify the resources, and forecast strategy more accurately and objectively.

Redefining the Path to Medical Breakthroughs

Under Tim Mikhelashvili's leadership, Amedea Pharma has embraced a forward-looking philosophy: innovation in medicine must be visible, collaborative, and fast-moving. The next generation of breakthroughs - whether in biotechnology, AI-driven diagnostics, or personalized therapeutics requires not only scientific excellence, but also access to capital, strategic partnerships, and global exposure. This is why it hosts one of the most intense and exciting, annual, global healthcare competitions in the world since 2022 - the Medical Innovation Olympics.

Amedea Pharma's approach is simple yet powerful: bring the world's most promising innovators into one arena, give them a platform and voice with which to present their work, challenge them, and connect them directly with decision-makers who can turn their concepts and products into life.

The Medical Innovation Olympics Format

Structured as a multi-stage competition with a build-up of intensity, the 2026 edition unfolded across key dates:

- **June 12, 2026** — Trials Session 1 **Live @Rockefeller Center + virtual**
- **September 18, 2026** — Trials Session 2 **@Rockefeller Center + virtual**
- **October 16, 2026** — Finals, Awards, Expert Panels, Closing Ceremony **Live @Rockefeller Center + virtual**

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005


WALLST
NEW YORK
TIM MIKHELASHVILI

AMEDEA PHARMA

BUILDING NEW HEALTHCARE CHAMPIONS

EDITORIAL BOARD | OCTOBER 16, 2026

The Journey behind Amedea's CEO

For more than two decades, Tim Mikhelashvili has walked the fault lines of the global pharmaceutical industry from large pharma (AstraZeneca, Sanofi) to startups, choosing truth over comfort and long-term impact over short-term optics. Tim describes his journey as one of perseverance and responsibility for character. Born in the Republic of Georgia and now based in New York, he is explicit about the greater responsibility he always felt: "For me, it was important to have impact on society, on my family, on my country where I was born, the Republic of Georgia, and also the country where I live, the United States." In his words, he wanted to be "a champion, surround himself with champions, and now he's building and seeking champions."

The turning point came in 2018. Tim was working at a startup with a best-in-class product that was failing not because of science, but because it was not operationalized or executed well. He spent two years convincing the Senior Executive Team to run proof-of-principle and head-to-head studies "considered too risky" that were published as late-breaking presentations at a major conference – and finally proved how a Medical team could re-energize an entire Sales Force, transform a launch, and grow $40 million in shareholder value in 4 hours after years of frustration in a small $300 million cap startup competing against a global large pharma market leader.

The lesson from his career, therefore, is that the industry does not lack innovation; it lacks visibility into how human behavior and internal workflows actually drive outcomes.

From Career Lesson to Timeless Proposal

He argues that medical and pharma roles are not purely technical; they are deeply behavioral. Executives, however, still frame performance in external technical terms, overlooking internal workflows and behaviors which are just as predictive of company and launch success based on Amedea's 2023 global benchmarking report.

ANCORA centralizes performance data across sales, marketing, and medical affairs and links it to behaviors, making attribution possible without undermining collaboration. Tim openly challenges the prevailing big-pharma stance that "it does not matter who drives outcomes as long as the patient gets the therapy," insisting that attribution is not about credit but about motivation, resource allocation, and "continuous quality improvement" so that teams do not hide behind enterprise results. When individuals or teams see clearly how their daily work counts, they stop hiding behind enterprise-level numbers and start competing to raise the bar – the same sports-driven inspiration for the Medical Innovation Olympics.

For investors, Amedea Pharma offers an intriguing proposition Tim describes as "very timely, but also very timeless." Timely, because AI is flooding the industry while leaders still struggle to centralize performance data, separate hype from value, and decide where to invest or cut. Timeless, because Amedea is building a continuous quality-improvement engine that sustains life science competitiveness in any macroeconomic or political climate.

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005

AMEDEA PHARMA

BUILDING NEW HEALTHCARE CHAMPIONS

EDITORIAL BOARD | OCTOBER 16, 2026

Where Science Meets Stage

Unlike traditional medical conferences, the Medical Innovation Olympics celebrates ane additional element to technical performance rarely seen in the scientific world: character.

Participants are evaluated not only on the strength of their science, but also its novelty, applicability, originality, relevance and causality and their ability to communicate it clearly. Each company is given a focused window to present, followed by in-depth discussions and editorial interviews that explore both the technology and the vision behind it.

This format transforms complex medical ideas into accessible, engaging narratives, opening the door for broader investment, media exposure, and public understanding.

The result is an unforgettable Olympic village environment where science does not sit quietly in journals, but instead takes center stage through the formula that combines learning, competing, and connecting.

A Global Gathering at Rockefeller Center

The choice of Rockefeller Center reflects both symbolism and strategy. Long associated with finance, culture, and international dialogue, it provides a powerful setting for an event designed to bridge industries and continents.

During each session of the Medical Innovation Olympics 2026, the venue will host a curated audience of healthcare leaders, institutional investors, policymakers, media organizations, and international delegates. This convergence creates a rare opportunity for innovators to engage directly with those who shape the future of healthcare on a global scale.

The Structure of Innovation

Each phase of the Medical Innovation Olympics is carefully designed to elevate participating companies.

Trials Session 1 (June 12, 2026) introduces a diverse group of medical innovators. Early-stage (CONCEPTS) and growth-stage (PRODUCTS) companies present their technologies to qualify for Olympics which kick off October 1 setting the tone for discovery and identifying ideas with transformative potential.

Trials Session 2 (September 18, 2026) builds on the foundation of Session 1 with a new set of competitors who test their capabilities to qualify for the Olympics October 1 over 2 rounds of competition. Olympic level innovation requires more than first impressions. It is timeless, and requires adaptability to feedback over time, thus those who qualify advance to Rounds 1 & 2 of Olympic competition which starts October 1.

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005



WALL ST

NEW YORK

TIM AND HIS WIFE &
CO-FOUNDER, IRINA

AMEDEA PHARMA
BUILDING NEW HEALTHCARE CHAMPIONS

EDITORIAL BOARD I OCTOBER 16, 2026

The Finals (October 16, 2026) represent the culmination of the journey. Finalists present at their highest level, competing not only for recognition but for meaningful opportunities—investment, partnerships, and global visibility.

This progression mirrors the lifecycle of innovation itself: ideation, validation, and realization.

Beyond Competition: Building an Ecosystem

While the format suggests competition, the deeper purpose of the Medical Innovation Olympics is collaboration.

Amedea Pharma has created an environment that celebrates dialogue, debate, and real-time live performance feedback where connections are deeper. Conversations that begin on stage often continue behind the scenes—leading to partnerships, joint ventures, and unexpected synergies.

Under Tim Mikhelashvili's direction with the Board of Investors, Healthcare Leaders, Executives and Scientists, the event is designed to fully replicate the Olympic format, intensity, quality, but also honor sportsmanship and character. It becomes a platform where every participant gains visibility, drives momentum, builds character and resilience.

In this sense, the Olympics is not defined by winners alone, but by the network it builds - a living ecosystem of innovators committed to advancing global healthcare.

Media, Visibility, and the Power of Narrative

A defining feature of the Medical Innovation Olympics is its integration with media and storytelling.


Each participating company receives the opportunity for professional editorial coverage, interviews, and visual features. This media presence plays a critical role in amplifying innovation, ensuring that groundbreaking ideas reach investors, partners, and the broader public.

By combining scientific rigor with compelling storytelling, Amedea Pharma ensures that innovation is not only developed but is also seen, understood, and supported.

A New Standard for Medical Innovation

As global healthcare systems face increasing complexity, the need for agile, high-visibility platforms has never been greater to ensure exciting medical innovation reaches patients. Amedea Pharma, under the leadership of Tim Mikhelashvili, is addressing this need by redefining how innovation is showcased and accelerated.

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005



2026 MEDICAL INNOVATION OLYMPICS

SPEAKERS & EXPERT PANELS

Recognizing the voices advancing access, quality and continuity of care.

JUNE 12 | RIBBON CUTTING & EXPERT PANEL

12:00-12:45 PM | EXPERT PANEL

From Promise to Proof of AI, Tech, & Systems in Healthcare

Tim Mikhelashvili CEO, Amedea Pharma
Tina Rezakhani Associate Director, Medical Affairs, Sanofi
Gregg A. Jackson COO / Investor, Manifold AI
Charles Legg Chief Operating Officer, CureLab Oncology
Srinivasan Krishnan Digital Products Lead, Regeneron

OCTOBER 1 | OPENING CEREMONY & ROUND 1

9:15-9:45 AM | EXPERT PANEL

The Decisions that Matter Today to Drive Life Science Deal-making with Impact

Scott Kelly CEO, Blackdog Ventures
Gregg Jackson Strategic Advisor, Manifold Health
Charles Legg Chief Operating Officer, CureLab Oncology
Chirag Lodhia Board Member, Burna AI

OCTOBER 8 | ROUND 2

9:00-9:45 AM | EXPERT PANEL

Innovation is Accelerating. Is Judgement Keeping Up?

Prem Sundivakkam Global Medical Affairs, Communications & Congress Leader, Pfizer
Cameron Tew CEO, Best Practices, LLC
Mike Rea Founder & former CEO, IDEA Pharma

OCTOBER 16 | FINALS & CLOSING CEREMONY

9:00-9:10 AM | HOSTS

Opening Remarks - Placing Humans First in the Age of AI

Tim Mikhelashvili CEO, Amedea Pharma
Shota Bagaturia CEO, NewsOut

9:10-9:40 AM | EXPERT PANEL


Building New Healthcare Champions with Sports Transparency and Competition

Tim Mikhelashvili CEO, Amedea Pharma
Chris Piedmonte Co-Founder & Managing Partner, Neoterra Capital
Graham Long Chief Commercial Officer, Amedea Pharma
Charles Legg Chief Operating Officer, CureLab Oncology
Chris Cook NHS UK Advisor & Double Olympian, Wondrous

9:40-10:10 AM | EXPERT PANEL

Redefining the Role of AI on Leadership, Talent, and Impact on Healthcare

Tala Fakhouri Chief AI & Regulatory Officer, Parexel
Sourav (Neil) Banerjee CEO & Founder, QMSintegrity LLC
Joao Dias Head, Global Scientific Affairs, Haemonetics
Venera Jordan Founder & Principal, DigitalProductGuru
Tim Mikhelashvili CEO, Amedea Pharma



2026 MEDICAL INNOVATION OLYMPICS

SPEAKERS & EXPERT PANELS

Recognizing the voices advancing access, quality and continuity of care.

OCTOBER 16 | FINALS & CLOSING CEREMONY CONTINUED

10:10-10:45 AM | EXPERT PANEL

Why Stars Are Aligning between Science and Advocacy to Extend Health Span and Longevity

Jerry McLaughlin CEO, Life Biosciences
Francisco Leon CEO, Tolerance Bio
John Hemming CEO, Cirrostratus Exedra Ltd
Keith Comito CEO, Lifespan Research Institute
Jonathan Ross Director of Operations, Alliance for Longevity Initiatives

11:00-11:15 AM | KEYNOTE

Epigenetic Restoration to Reverse Age-related Diseases

Michael Ringel Chief Operating Officer, Life Biosciences

11:15-11:45 AM | KEYNOTE

The Power of Many Voices: The Future of Oncology Is More Connected, More Collaborative, and Built Together

Kirk Shepard Chief Medical Officer, PDS Biotechnology

11:45 AM-12:15 PM | KEYNOTE

New Age of Cardiometabolic Disease Prevention, Evidence and Access to Innovation

Keith Ferdinand Chair, Preventative Cardiology, Tulane University School of Medicine

12:15-12:30 PM | KEYNOTE

Extending Global Impact of Medical Affairs across Stages of Drug Development

Alex Palumbo Founder & CEO, Medscion

1:30-1:50 PM | FIRESIDE CHAT

Navigating a Passage to Successful Access to Medical Innovation

Alan Gray Partner, US Market Access and Pricing, Alira Health

1:50-2:10 PM | FIRESIDE CHAT

Building a Winning Strategy and Capital in Private Stage Biotechs

Stephen Mitchener Former Chief Business Officer, Alpha-9 Oncology

2:10-2:30 PM | EXPERT PANEL

From Innovation to Impact on Patient Outcomes

Rashad Massoud Head, Global Health USA, IQVIA
Eric Griggs International Health & Wellness Ambassador, US Congress - Louisiana
Nino Mikaberidze Co-Founder, MedVeritas Global
Mackenzie Howe Co-Founder & CEO, Atheni

WALL ST

amvea PHARMA

SCAN QR CODE BELOW TO SCHEDULE A MEETING

NEW YORK

AMEDEA PHARMA AND THE RISE OF A NEW MEDICAL FRONTIER

EDITORIAL BOARD I OCTOBER 16, 2026

The Human Element of High Performance
At its core, the Medical Innovation Olympics celebrates the power of human character.

Behind every presentation is a story – researchers driven by curiosity, entrepreneurs and healthcare champions guided by only two directions in their life compass – progress and success, who celebrate the art of performance, take advantage of the power of competition and transparency to drive their growth, and challenge themselves with live voting and real-time feedback from all-star investors and industry expert judges, united by the desire to solve some of the world's most pressing health challenges.

These stories bring energy and meaning to the event, reminding audiences that innovation is deeply human, requiring personality, empathy, and resilience not solely science or technique.

From emerging founders presenting their first breakthroughs and CONCEPTS to experienced leaders unveiling next-generation technologies and mature PRODUCTS, the event captures the full spectrum of the medical innovation journey.

Looking Ahead
Recognized by Fierce Pharma as one of the Top 4 Innovation Challenges in the world in 2025, its 2026 edition, the Medical Innovation Olympics, #MIO2026 broke new records with its largest global audience to date spread across 11 countries

For Amedea Pharma, this is only the beginning. The company envisions a future where where the best ideas are not limited by geography or access, but are instead given a global stage worthy of their potential.

This is the forum where leaders address topics years before they go mainstream, where they debate the purpose of innovation and mission to make larger, more global impact in healthcare. Competition is at the epicenter, yet side-by-side with intensity, sportsmanship and responsibility for the kind of innovation leaders are bringing to society for generations to come.

All six #MIO2026 medalists have earned the chance to present to investors at the 2027 J.P. Morgan Healthcare Conference Week in San Francisco on January 11 and 12.

Stage for the Future of Medicine
What ideas will emerge? Which breakthroughs will shape the future of healthcare next year, in 2027?

These questions are part of the excitement.

What is certain, however, is this: through Amedea Pharma and the Medical Innovation Olympics 2026, a modern vision of leadership in healthcare is taking shape – one where science, entrepreneurship, and global collaboration converge.

And from that convergence, the future of medicine begins.

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005

WALL ST

AMEDEA PHARMA

BUILDING NEW HEALTHCARE CHAMPIONS



CLICK QR OR SCAN
TO WATCH

NEW YORK

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005

JESSICA REED, CEO OF DIAPIN THERAPEUTICS: ADVANCING CARDIOVASCULAR INNOVATION AND PREVENTING HEART ATTACKS AND STROKES

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER

INTERVIEW BY SHOTA BAGATURIA | OCTOBER 16, 2026

Wall St New York Magazine: Please tell us about yourself and DIAPIN Therapeutics.

Jessica Reed: I'm Jessica Reed, CEO of DIAPIN Therapeutics, a biotechnology company spun out of the University of Michigan and based in Ann Arbor, Michigan. We have two drugs in development. Our lead asset is an antiplatelet therapy designed to prevent blood clots that can cause heart attacks and strokes. We are working to address one of the leading causes of death for both men and women, making this research particularly important for cardiovascular health.

Approximately 60% of strokes occur in women, which further highlights the importance of developing effective cardiovascular treatments that address women's health needs.

Our second drug targets inflammatory disorders and atherosclerosis. We have recently completed the studies needed to support preparation for an Investigational New Drug (IND) application, and while this program is at an earlier stage, we are excited about the potential of both therapies.

Wall St New York Magazine: How can investors participate in funding the company's development?

Jessica Reed: We are currently raising a seed round. We have $4 million committed and are seeking an additional $3.5 million. This funding will support the development of our lead asset toward the New Drug Application (NDA) submission stage and help advance its potential future approval and use in patients in the United States.

Funding is essential to support our research and complete the studies required by the U.S. Food and Drug Administration (FDA). We see a significant opportunity to advance this promising therapy, but we need investment to reach the next major milestones.

Wall St New York Magazine: Where is DIAPIN Therapeutics based, and how did the company originate?

Jessica Reed: DIAPIN Therapeutics is based in Ann Arbor, Michigan, and originated as a spinout from the University of Michigan Medical School. Our lead asset was discovered at the university by Paul Hollingworth and Howming Zhang.

The molecule is innovative because it is metabolized differently in the body while producing the same active metabolite as clopidogrel, a well-established antiplatelet medication with a long history of use. Its improved metabolism may allow it to work effectively in a broader range of patients.

The company was founded by Dr. Eugene Chen, and Dr. Charlie Bisgaier serves as chairman of the board. Both have dedicated their careers to cardiovascular research and bring substantial expertise to the development of our company and its therapies.

Our goal is to reduce the risks of heart attacks, strokes, and cardiovascular disease more broadly, ultimately helping save lives.

JESSICA REED, CEO OF DIAPIN THERAPEUTICS: ADVANCING CARDIOVASCULAR INNOVATION AND PREVENTING HEART ATTACKS AND STROKES

DIAPIN Therapeutics

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER

INTERVIEW BY SHOTA BAGATURIA | OCTOBER 16, 2026

Wall St New York Magazine: What has your experience been like participating in the Medical Innovation Olympics?

Jessica Reed: I was invited to participate in the Medical Innovation Olympics and progressed through several rounds of competition. The other competitors challenged me to improve my presentation and communicate our work more effectively, and I learned a great deal throughout the process.

It has been a wonderful experience. Meeting Olympic athletes, outstanding CEOs, and people from across the country has been inspiring. The competition combines learning, networking, and the opportunity to share innovative healthcare solutions with a broader audience. I've really enjoyed being part of it.

Wall St New York Magazine: Tell us about your professional background and what led you to DIAPIN Therapeutics.

Jessica Reed: I'm originally from the United Kingdom and hold a PhD in chemistry from the University of Leeds. I came to the United States to complete a postdoctoral position at the University of Rochester before being recruited to work at Parke-Davis in Ann Arbor, Michigan.

Parke-Davis was the original developer of several highly successful medicines, including Lipitor, Lyrica, and Ibrance. The company was subsequently acquired by Pfizer. It was a wonderful place to work, and I developed valuable experience in pharmaceutical research and development.



Rockefeller Center, New York

JESSICA REED, CEO OF DIAPIN THERAPEUTICS: ADVANCING CARDIOVASCULAR INNOVATION AND PREVENTING HEART ATTACKS AND STROKES

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER

INTERVIEW BY SHOTA BAGATURIA | OCTOBER 16, 2026

also came to appreciate Ann Arbor as a great place to live, so I stayed in the area and worked with several other pharmaceutical and biotechnology companies before joining DIAPIN Therapeutics.

My background in chemistry and pharmaceutical development has helped prepare me for the challenge of advancing innovative therapies from scientific discovery toward potential clinical use.

Wall St New York Magazine: What is the broader mission of DIAPIN Therapeutics?

Jessica Reed: Our mission is to develop innovative therapies that address important unmet medical needs, particularly in cardiovascular disease. Heart attacks and strokes have devastating consequences for patients and their families, and we believe there is an opportunity to improve treatment options through better scientific understanding and drug development.





We are committed to advancing our research, securing the funding needed to reach key development milestones, and ultimately bringing effective new treatment options to patients.

Wall St New York Magazine: Jessica, thank you for sharing your work and vision with our readers.

Jessica Reed: Thank you. It has been a pleasure.

WALL ST

DIAPIN Therapeutics

JESSICA REED, CEO OF DIAPIN THERAPEUTICS: ADVANCING CARDIOVASCULAR INNOVATION AND PREVENTING HEART ATTACKS AND STROKES

MEDICAL INNOVATION OLYMPICS



CLICK QR OR SCAN TO WATCH

NEW YORK

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005

ENAMEL PURE: REVOLUTIONIZING DENTAL HYGIENE THROUGH LASER TECHNOLOGY

A New Era in Preventive Dentistry

The global healthcare industry is experiencing a technological transformation, with innovative companies introducing solutions designed to improve patient outcomes, increase clinical efficiency, and modernize traditional medical procedures. Among these emerging innovators is Enamel Pure, a dental technology company developing a new approach to professional teeth cleaning through advanced laser technology.

For decades, dental hygiene has remained one of the most routine yet technologically underserved areas of healthcare. While dentistry has witnessed significant progress in digital imaging, orthodontics, implants, and cosmetic procedures, conventional professional teeth cleaning continues to rely heavily on mechanical instruments, physical contact, and established clinical techniques.

Enamel Pure seeks to change that model. According to market figures provided by the company, more than $16 billion is spent annually on over 150 million professional teeth-cleaning appointments. This substantial market represents an opportunity for technological innovation, particularly as dental practices seek to improve efficiency, patient satisfaction, and long-term preventive care.

Enamel Pure is introducing its Lune laser, a device designed to clean teeth, strengthen enamel, and reduce gum bacteria through a non-contact approach.

The company's vision extends beyond simply replacing conventional dental instruments. It aims to redefine professional hygiene appointments by combining cleaning, enamel protection, and preventive treatment into a more efficient clinical experience.

Rather than focusing exclusively on removing accumulated deposits, Enamel Pure's technology is intended to help protect the underlying structures of teeth while supporting healthier gums and improving the effectiveness of additional dental treatments.



WALL ST
NEW YORK
MAGAZINE

ENAMEL PURE: REVOLUTIONIZING DENTAL HYGIENE THROUGH LASER TECHNOLOGY

Transforming a $16 Billion Dental Hygiene Market

Dental hygiene is a particularly attractive segment for innovation because of its enormous patient volume, recurring appointments, and established demand. Unlike specialized dental procedures that may occur only once or twice during a patient's lifetime, professional teeth cleaning is typically recommended at regular intervals, creating a consistent relationship between patients and dental providers.

For dental practices, however, traditional hygiene appointments require substantial investments in professional labor, clinical equipment, scheduling, and treatment time.

Enamel Pure believes that improving the efficiency of these appointments could create significant economic benefits for both providers and patients.
The company describes its laser-based technology as potentially twice as fast as conventional cleaning methods, with a quiet, non-contact process designed to reduce discomfort.

This combination of efficiency and patient comfort could help dental offices accommodate additional appointments, improve the utilization of clinical resources, and reduce some of the operational pressures associated with high-volume hygiene services.

A procedure that requires less chair time could also make preventive dental care more accessible to patients balancing professional responsibilities, family schedules, and other commitments.

From a business perspective, Enamel Pure's proposed model offers the possibility of improving productivity without requiring dental practices to abandon their existing preventive-care relationships.

Instead, its technology is designed to integrate into the established dental hygiene market while potentially increasing the value of each appointment through additional enamel-protection benefits.

The company's opportunity therefore extends beyond equipment innovation. It encompasses a broader effort to modernize the economics and patient experience of preventive dentistry.
The Lune Laser: Cleaning, Strengthening, and Protecting Teeth

ENAMEL PURE: REVOLUTIONIZING DENTAL HYGIENE THROUGH LASER TECHNOLOGY

At the center of Enamel Pure's innovation is the Lune laser, which the company is developing as a multifunctional dental hygiene platform.

Traditional professional cleaning procedures frequently involve ultrasonic scalers, manual instruments, polishing compounds, and other tools that physically interact with tooth surfaces. Although these methods remain widely used and clinically established, some patients experience sensitivity, discomfort, vibration, or anxiety during treatment.



Enamel Pure proposes an alternative built around laser-based interaction with the tooth surface.

According to the company, its technology is designed to deliver three principal benefits: cleaning teeth, hardening enamel, and reducing gum bacteria.

The proposed enamel-hardening capability is particularly important because enamel plays a fundamental role in protecting teeth against decay, erosion, and sensitivity.

Enamel is the hardest substance in the human body, yet it remains vulnerable to acid exposure, bacterial activity, dietary habits, and mechanical wear. Once significant enamel structure is lost, the body cannot naturally regenerate it in the same manner as living tissue.

Consequently, technologies that can help preserve enamel integrity may offer meaningful benefits for long-term oral health.

Enamel Pure's approach reflects a shift in preventive dentistry from treating problems after they develop toward protecting dental structures before irreversible damage occurs.

The company also positions its laser treatment as complementary to existing dental services, including whitening, fluoride applications, and remineralization gels.

WALL ST
NEW YORK
MAGAZINE

ENAMELPURE

EXCLUSIVE INTERVIEW WITH NATHAN MONTY



CLICK QR OR SCAN
TO WATCH

WALL ST NEW YORK

CHRIS STURM – BRONZE MEDALIST IN THE PRODUCT CATEGORY FACET DYNAMICS

WALL ST NEW YORK MAGAZINE
EDITORIAL BOARD I OCTOBER 16, 2026



Facet Dynamics, Inc. is a medical start-up company that has developed "Restore", a completely novel thoracolumbar facet arthroplasty device, designed to provide a superior alternative to today's fusion procedures. It is an "Artificial Back Joint", akin to today's artificial hip and knee joints, manufactured from the exact same materials, and with the same design premise: reproduce the pertinent anatomic structures of the joint in order to reproduce the joint's function. Restore provides the required translational stability and resistance to axial rotation, while facilitating the primary vectors of movement in the lumbar spine, flexion and extension, thereby avoiding adjacent segment disease, which occurs due to the altered biomechanics incumbent with fusion procedures. Restore, which at present is "Investigational Use Only", is a unilateral device, which can be implanted either unilaterally or bilaterally.

This capability provided by Restore enables surgeons to custom tailor the surgical intervention. This unique capability also opens the door for several additional indications. The only FDA approved facet arthroplasty device in the U.S. market. TOPS (Premia Spine), is a bilateral engineered device, not an anatomic representation, and does not allow for individualized intervention. It is an "all or nothing" situation, and all the anatomic structures at the treated level must be removed in order to implant TOPS, whether they are diseased or not. Restore is also perfectly amenable to minimally invasive surgical techniques and incorporation into ambulatory surgical centers, which is not the case with TOPS. Unique not only in its design and implementation, Restore embodies a completely novel approach to the surgical management of spinal degenerative disease.

Unlike fusion procedures, which attempt to force the spine to behave in a manner completely opposite of what was intended, Restore is designed to work in concert with the structures at the index level, providing stability and motion.

WALL ST

ADELLE DIAGNOSTICS INC.
Inside into the unseen



ADELLE DIAGNOSTICS (ADDX): REDEFINING NEUROLOGICAL CARE THROUGH AI-POWERED MOLECULAR INTELLIGENCE

MEDICAL INNOVATION OLYMPICS

NEW YORK

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005

ADELLE DIAGNOSTICS (ADDX): REDEFINING NEUROLOGICAL CARE THROUGH AI-POWERED MOLECULAR INTELLIGENCE

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD | OCTOBER 16, 2026

In the rapidly evolving landscape of precision medicine, few frontiers present as much urgency—and opportunity—as neurological disease. Conditions such as Alzheimer's, Parkinson's disease, and Normal Pressure Hydrocephalus (NPH) affect millions globally, yet diagnostic accuracy and treatment decision-making remain deeply constrained by subjective clinical assessments and incomplete biological insight. Against this backdrop, Adelle Diagnostics (AdDx) emerges as a transformative force, introducing a new paradigm where artificial intelligence and molecular biology converge to enable predictive, personalized care.

A spin-out from Brown University, AdDx represents the intersection of cutting-edge neuroscience, machine learning, and translational medicine. Founded by CEO Maria Grazia Ruocco, alongside neuroscientist and computer scientist Alex Fleischmann and Thomas Serre, the company is pioneering a platform that seeks to fundamentally change how neurological diseases are diagnosed and treated—before irreversible damage occurs.

At the heart of AdDx's innovation lies DIMA™ (Diagnostics by Molecular Association), a proprietary foundation model platform designed to uncover complex biomarker signatures from biofluids such as cerebrospinal fluid (CSF). Unlike traditional diagnostics, which often rely on single biomarkers or imaging findings, DIMA leverages AI to identify patterns across multiple molecular signals, enabling clinicians to predict how a patient will respond to treatment even before the first clinical decision is made.

This predictive capability marks a paradigm shift. In neurology, where trial-and-error approaches often delay effective treatment, DIMA introduces a proactive, biology-driven framework. By decoding molecular signatures at scale, AdDx is positioning itself at the forefront of precision diagnostics—bringing clarity to conditions that have long been characterized by uncertainty.

ShuntIQ™: Addressing a Critical Gap in Dementia Care

AdDx's first clinical application, ShuntIQ™, exemplifies the company's mission to translate advanced science into tangible patient outcomes. The test targets Normal Pressure Hydrocephalus (NPH), a frequently overlooked and treatable form of dementia, in which excess cerebrospinal fluid builds up in the brain's cavities. Despite being one of the few reversible causes of dementia, NPH remains widely underrecognized—up to 80% of cases are either missed entirely or misdiagnosed as other neurodegenerative conditions, most commonly Alzheimer's disease.

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005

ADELLE DIAGNOSTICS (ADDX): REDEFINING NEUROLOGICAL CARE THROUGH AI-POWERED MOLECULAR INTELLIGENCE

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD | OCTOBER 16, 2026

The consequences of misdiagnosis are profound. Patients who could benefit from a relatively straightforward surgical intervention—ventriculoperitoneal shunting—are instead left untreated, experiencing progressive cognitive and functional decline. Conversely, patients who undergo unnecessary procedures face avoidable risks without clinical benefit.

ShuntIQ addresses this diagnostic gap with unprecedented precision. Utilizing a 16-metabolite panel derived from CSF and selected through the DIMA platform, the test predicts a patient's likelihood of responding to shunt surgery and its scientific foundation is supported by both published and peer-reviewed research currently under submission. This evidence-based approach, alongside partnerships with Rhode Island Hospital, reinforces AdDx's commitment to clinical rigor and positions the company for accelerated adoption within the medical community.

Building the Infrastructure for Scalable Impact

As AdDx advances its flagship product, the company is simultaneously laying the groundwork for broader platform expansion. Currently, AdDx is raising a $2 million seed round aimed at achieving several critical milestones. These include completing analytical validation across a cohort of 250 patients spanning more than ten clinical sites, advancing laboratory-developed test (LDT) capabilities through a CLIA-certified lab partner, and initiating pre-submission discussions with the U.S. Food and Drug Administration (FDA).

This strategic roadmap reflects a disciplined approach to commercialization—balancing speed with regulatory and scientific integrity. By establishing a validated and reimbursable pathway through its NPH application, AdDx is creating a scalable framework that can be extended to other neurological conditions.

The implications are significant. Alzheimer's disease and Parkinson's disease alone represent multi-billion-dollar markets with vast unmet diagnostic needs. Current tools often detect disease only after substantial neurological damage has occurred, limiting therapeutic effectiveness. By contrast, AdDx's DIMA platform aims to enable earlier detection, stratify patients based on treatment response, and ultimately support the development of more targeted therapies.

A Platform for the Future of Medicine

What distinguishes AdDx is not merely its first product, but the extensibility of its underlying technology. DIMA is designed as a foundation model—capable of continuously learning from new data,


MEDICAL INNOVATION OLYMPICS
WALL ST
NEW YORK
TINA REZAKHANI
VENERA JORDAN
TIM MIKHELASHVILI
MARIA GRAZIA RUOCCO
SHOTA BAGATURIA

ADELLE DIAGNOSTICS INC.
Inside into the unseen

Sample Collection	Single Omics	Complexity Reduction	Omics Integration	Product Biomarker
				
CLINICAL AND NEUROLOGICAL EXAMS IMAGING SPINAL TAP	ELISA RNA-SEQ MASS SPEC	PATHWAY ANALYSIS	MATHEMATICAL MODEL STATISTICS & MACHINE LEARNING	MECHANISTIC INTERPRETATION DIAGNOSIS & SHUNT BENEFIT PREDICTION

ADELLE DIAGNOSTICS (ADDX): REDEFINING NEUROLOGICAL CARE THROUGH AI-POWERED MOLECULAR INTELLIGENCE

MEDICAL INNOVATION OLYMPICS

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005

ADELLE DIAGNOSTICS (ADDX): REDEFINING NEUROLOGICAL CARE THROUGH AI-POWERED MOLECULAR INTELLIGENCE

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD | OCTOBER 16, 2026

refining biomarker discovery, and expanding its predictive capabilities across multiple disease states.

This positions AdDx within a broader shift toward AI-driven healthcare ecosystems, where data integration and machine learning unlock insights that were previously inaccessible. As healthcare systems worldwide grapple with rising costs and aging populations, solutions that improve diagnostic accuracy and optimize treatment pathways are becoming increasingly essential.

Moreover, AdDx's approach aligns with the growing emphasis on personalized medicine. By moving beyond one-size-fits-all diagnostics, the company is enabling a more nuanced understanding of disease—one that accounts for individual variability at the molecular level.

Leadership and Vision

The strength of AdDx's vision is matched by the expertise of its founding team. Maria Grazia Ruocco brings strategic leadership and a deep commitment to translating scientific innovation into clinical impact. Her collaboration with Alex Fleischmann and Thomas Serre—leaders in neuroscience and artificial intelligence—creates a multidisciplinary foundation that is critical for success in this complex domain.

Together, the team embodies a new generation of biotech leadership: one that seamlessly integrates computational intelligence with biomedical research to address some of the most challenging problems in medicine.

Conclusion: A Defining Moment in Neurological Diagnostics

As Adelle Diagnostics moves from early-stage development toward clinical and commercial realization, its trajectory reflects a broader transformation within healthcare. The convergence of AI, molecular science, and clinical data is redefining what is possible—not only in diagnosis, but in the entire continuum of care.

With ShuntIQ poised to address a critical gap in dementia treatment and DIMA offering a scalable platform for future applications, AdDx stands at the forefront of this transformation. Its work signals a shift from reactive to predictive medicine, where decisions are guided not by uncertainty, but by data-driven insight.

For investors, clinicians, and patients alike, Adelle Diagnostics represents more than a promising startup—it represents a new standard for how neurological disease can be understood, diagnosed, and ultimately treated.

WALL ST

ADELLE DIAGNOSTICS (ADDX): REDEFINING NEUROLOGICAL CARE THROUGH AI-POWERED MOLECULAR INTELLIGENCE

MEDICAL INNOVATION OLYMPICS



CLICK QR OR SCAN TO WATCH

NEW YORK

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005

CALARIS DIAGNOSTICS: REDEFINING EARLY DETECTION THROUGH NON-INVASIVE PRECISION

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD | JUNE 12, 2026

Calaris Diagnostics

Calaris Diagnostics: Bringing Early Detection to the Frontlines of Care

Healthcare innovation is often measured by breakthroughs in treatment – but the greatest opportunity may lie earlier, at the moment a disease is first detected. For millions of patients, diagnosis still comes too late, not because the science doesn't exist, but because the system makes early testing difficult to access.

Calaris Diagnostics is part of a new wave of companies working to solve this problem at its root. By transforming saliva into a clinically meaningful diagnostic tool, the company is developing a platform that shifts testing out of specialized settings and into everyday healthcare environments.

The ambition is straightforward yet profound: make early detection simple, fast, and available wherever patients already are.

Rethinking the First Step in Medicine

The traditional diagnostic pathway is built on complexity. Blood tests, imaging scans, and specialist referrals often require time, infrastructure, and coordination – factors that can delay detection, particularly for patients in early or asymptomatic stages.

Calaris Diagnostics approaches the problem differently. Instead of asking patients to navigate the system, it brings the test to the patient.

Saliva, long considered a secondary biological fluid, becomes the entry point. Easy to collect and non-invasive, it eliminates one of the most immediate barriers to testing – patient reluctance. But accessibility alone is not enough. The challenge lies in extracting meaningful clinical data from a medium historically limited by low biomarker concentration.


Calaris addresses this through a combination of refined assay design and computational analysis, enabling saliva to deliver insights that can support real clinical decisions.

A Platform Built for Real-World Healthcare

At the center of the company's development pipeline is its saliva-based diagnostic platform, designed to function in environments where traditional testing is impractical.

Rather than focusing solely on laboratory precision, Calaris prioritizes usability and scalability. The goal is to create tests that can be administered quickly in primary care offices, dental clinics, and community health settings – places where early signs of disease are most likely to be overlooked.

This shift reflects a broader evolution in healthcare: moving from centralized, reactive models to decentralized,


Calaris Diagnostics
WALL ST
NEW YORK

MYCAZED: REVOLUTIONIZING ANTIFUNGAL TREATMENT THROUGH INNOVATIVE DRUG DELIVERY TECHNOLOGY
MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD I OCTOBER 16, 2026

Exclusive Interview with David Larwood, Founder of MycaZED

Interview by Shota Bagaturia | Wall St New York Magazine

Headquartered in Tucson, Arizona, MycaZED is an emerging pharmaceutical company dedicated to developing advanced antifungal therapies targeting serious fungal infections, including Valley fever. Led by pharmaceutical scientist and inventor David Larwood, the company has developed an innovative drug-delivery approach that has reportedly increased the potency of an antifungal compound by a factor of 30.

Building on decades of experience in pharmaceutical innovation, MycaZED aims to improve treatment options for patients affected by fungal diseases worldwide. The company is currently seeking $2 million in financing to advance its regulatory development, pursue an Investigational New Drug (IND) application, and explore additional therapeutic indications.

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005

Inanna Certifications

MYCAZED: REVOLUTIONIZING ANTIFUNGAL TREATMENT THROUGH INNOVATIVE DRUG DELIVERY TECHNOLOGY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD | OCTOBER 16, 2026

Wall St New York Magazine: David, thank you for joining us at the Medical Innovation Olympics. Could you introduce yourself and explain the mission behind MycaZED?

David Larwood: Thank you for having me. We're very excited about MycaZED and the potential of our antifungal technology. I've worked on Valley fever for many years, and it remains a disease with significant medical challenges.

At MycaZED, we've developed a more effective way of delivering an antifungal drug. Through our research, we've observed an increase in potency by a factor of 30, which we believe represents a significant advancement.

Our approach has demonstrated very promising results against Valley fever, and we believe it could also be useful against several other fungal diseases that have a major impact on patients worldwide.

Wall St New York Magazine: Where is MycaZED based, and how is the company positioned for future growth?

David Larwood: We're based in Tucson, Arizona. Right now, I'm the only full-time employee, but we have additional professionals ready to come on board as the company advances.

We're keeping our operations focused while concentrating on the scientific and regulatory milestones necessary to bring our technology forward. As we secure additional funding, we'll be able to expand our team and accelerate development.

Wall St New York Magazine: MycaZED is currently seeking investment. What are your funding objectives, and how would this capital help advance the company's development?

David Larwood: We're looking to raise approximately $2 million, primarily to support an Investigational New Drug application, or IND.

Our objective is to accelerate development of an existing product from a companion company while expanding the potential indications for our antifungal technology.

MYCAZED: REVOLUTIONIZING ANTIFUNGAL TREATMENT THROUGH INNOVATIVE DRUG DELIVERY TECHNOLOGY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD | OCTOBER 16, 2026

We'll initially focus on Valley fever, which has been a central part of my research for many years. However, we're also interested in additional fungal infections, including aspergillosis.

These diseases represent a substantial medical burden in the United States and globally. We see significant opportunities to develop more effective therapies, and the funding would help us move through the necessary regulatory stages.

Wall St New York Magazine: What distinguishes MycaZED's technology from traditional antifungal treatments?

David Larwood: The most important difference is how we deliver the drug.

We've developed a method that significantly improves the potency of an antifungal compound. In our research, we've seen a 30-fold increase in potency through this improved delivery approach.

That's an important distinction because the effectiveness of a drug isn't determined solely by the active compound. The way it's delivered can dramatically influence how well it performs.

We believe our technology could make existing antifungal treatments substantially more effective and potentially expand their applications to additional diseases.

Wall St New York Magazine: How did you become involved with the Medical Innovation Olympics, and what has your experience been like?

David Larwood: I met Tim through another organization I'm involved with, and he encouraged me to participate in the Medical Innovation Olympics.

I began exploring the online presentations and was impressed by the quality of the speakers, the motivational stories, and the business expertise represented throughout the program.

The experience has been excellent. Both the online sessions and the panel discussions here have provided valuable perspectives.

It's particularly encouraging to be surrounded by people who understand the importance of innovation and the challenges of transforming scientific discoveries into successful medical products.

MYCAZED: REVOLUTIONIZING ANTIFUNGAL TREATMENT THROUGH INNOVATIVE DRUG DELIVERY TECHNOLOGY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD I OCTOBER 16, 2026

Wall St New York Magazine: Your career in pharmaceutical science spans several important medical innovations. What initially inspired you to pursue this field?

David Larwood: My father was a physician, and he originally intended to become a medical missionary in a very poor country.

Unfortunately, those plans didn't work out, and our family eventually returned to the United States. Nevertheless, his dedication to medicine and helping others had a profound influence on me.

I ultimately decided to pursue a career in drug science, where I could combine scientific discovery with the opportunity to improve human health.

Over the years, I've been fortunate to invent technologies that were subsequently commercialized and contributed to medical treatments used by large numbers of patients.

Wall St New York Magazine: Could you share some of your most significant inventions and their contributions to modern medicine?

David Larwood: One of my early inventions was an X-ray contrast agent used in medical diagnosis. That product was commercialized and remained on the market for approximately 20 years.

Another important contribution was my invention of PEGylated lipids. I was the first person in the world, to my knowledge, to create a PEGylated lipid.

This technology allows scientists to develop PEGylated liposomes, which are microscopic structures that can encapsulate therapeutic substances.

I often describe them as tiny, fuzzy spheres. You can place a drug or another therapeutic substance inside the structure, where it's protected from the surrounding environment.

This concept became important in pharmaceutical drug delivery because it provided new ways to transport therapeutic compounds through the body.

Wall St New York Magazine: How did your work with PEGylated lipids influence cancer treatment and the development of newer medical technologies?

MYCAZED: REVOLUTIONIZING ANTIFUNGAL TREATMENT THROUGH INNOVATIVE DRUG DELIVERY TECHNOLOGY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD I OCTOBER 16, 2026

David Larwood: One major application of this type of technology is Doxil, a liposomal formulation of doxorubicin, which is an anticancer drug.

Doxil has been commercially available for decades, demonstrating the importance of advanced drug-delivery systems in cancer treatment.

The broader field of lipid-based drug delivery has also played a significant role in the development of messenger RNA vaccines.

These systems allow scientists to package sensitive biological materials and protect them until they reach their intended destination.

The technology used in modern mRNA vaccines represents an evolution of scientific principles that were central to my thesis research.

It's fascinating to see how an invention developed many years ago can contribute to entirely new generations of medical technology.

Wall St New York Magazine: Having contributed to multiple generations of pharmaceutical innovation, what motivates you to continue developing new therapies through MycaZED?

David Larwood: What motivates me is the opportunity to solve important medical problems.

I've spent much of my career working on technologies that can improve how drugs are delivered and how effectively they work.

With MycaZED, we're applying that experience to fungal diseases that continue to affect patients and present significant treatment challenges.

Valley fever is particularly important to me because I've worked on it for so many years. I believe our technology has the potential to make a meaningful difference.

The next step is securing the resources necessary to advance development and move toward clinical evaluation.

MYCAZED: REVOLUTIONIZING ANTIFUNGAL TREATMENT THROUGH INNOVATIVE DRUG DELIVERY TECHNOLOGY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD | OCTOBER 16, 2026

Wall St New York Magazine: What opportunities do you see for investors and strategic partners interested in supporting MycaZED?

David Larwood: We're seeking approximately $2 million to support our next stage of development, particularly the IND process and expansion of our antifungal program.

We believe the technology offers an attractive opportunity because we're building on an existing antifungal compound while introducing an improved delivery method.

Our initial focus is Valley fever, but we're also exploring applications against other fungal infections with substantial medical needs.

We're interested in working with investors and partners who recognize both the scientific potential and the importance of bringing better antifungal treatments to patients.

Wall St New York Magazine: Finally, what would you like to share with fellow innovators and entrepreneurs participating in the Medical Innovation Olympics?

David Larwood: Innovation requires persistence, collaboration, and a willingness to pursue ideas that can make a difference.

I've had the privilege of working on pharmaceutical technologies that eventually became commercially successful medical products, and I know that bringing scientific discoveries to patients requires considerable effort.

The Medical Innovation Olympics provides an excellent environment for connecting scientific innovation with business experience and potential partnerships.

I've really enjoyed the presentations, the panel discussions, and the opportunity to meet people who are passionate about improving medicine.

I'm grateful to be part of the program and excited about what lies ahead for MycaZED.

Wall St New York Magazine: David, thank you for sharing your remarkable scientific journey .

David Larwood: Thank you very much. It's been a pleasure being here.

WALL ST

EXCLUSIVE INTERVIEW WITH DAVID LARWOOD, FOUNDER OF MYCAZED



CLICK QR OR SCAN TO WATCH

NEW YORK

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005

Exclusive Interview with Ron of Pinnacle Technology Partners (PTP)

Interview by Shota Bagaturia | Wall St New York Magazine

As biotechnology and artificial intelligence increasingly converge, emerging life sciences companies face a critical challenge: developing the technological infrastructure necessary to transform scientific discoveries into commercially viable businesses.

For many biotechnology startups, limited financial resources, complex regulatory requirements, and the need for sophisticated computing environments can create significant obstacles to growth.

Pinnacle Technology Partners (PTP), a managed services provider specializing in cloud infrastructure, artificial intelligence, and IT solutions, is helping companies overcome these challenges through its strategic relationships with major technology providers, including Amazon Web Services (AWS).

With approximately 10 AWS certifications and a team of more than 250 employees across the United States and India, PTP supports biotechnology companies throughout their development, from early-stage research and seed funding to commercial operations and potential public offerings.

During the Medical Innovation Olympics, Wall St New York Magazine spoke with Ron, a PTP representative with a background in bioinformatics and computational science, about the company's approach to accelerating biotech innovation, supporting startup funding, and creating secure, scalable infrastructure for the next generation of healthcare and life sciences businesses.

ACCELERATING BIOTECH INNOVATION: HOW PTP HELPS LIFE SCIENCES STARTUPS BUILD SECURE AI INFRASTRUCTURE, ACCESS CLOUD FUNDING, AND SCALE TOWARD IPO

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER

INTERVIEW BY SHOTA BAGATURIA | OCTOBER 16, 2026

Wall St New York Magazine: Please tell us about yourself, your professional background, and Pinnacle Technology Partners. What is the company's primary mission?

Ron: Thank you for having us. It's been a really great experience for both myself and Pinnacle Technology Partners.

My background is in bioinformatics and computational science, which gives me a strong understanding of the technological challenges facing biotechnology and life sciences companies.

Pinnacle Technology Partners, or PTP, is a managed services provider specializing in IT infrastructure, cloud computing, artificial intelligence, and technology solutions for startups and established businesses.

We have approximately 10 certifications with Amazon Web Services, and our capabilities are particularly focused on biotechnology and life sciences.

What that means in practical terms is that we help companies build and manage the technology infrastructure they need to operate, grow, and scale.

Whether we're working with an early-stage biotechnology startup, a midsize company, or a large pharmaceutical organization, our objective is to provide the technical foundation that allows them to focus on innovation and business development.

We can support everything from infrastructure and IT operations to artificial intelligence, bioinformatics workflows, and security.

Ultimately, our mission is to help life sciences companies get off the ground and continue supporting them as they grow.

Wall St New York Magazine: PTP has developed a strong relationship with Amazon Web Services. How does this partnership benefit biotechnology startups, particularly those with limited financial resources?

Ron: Our relationship with AWS is one of the most exciting aspects of what we do because it allows us to provide significant value to emerging biotechnology companies.

We also work with other major technology providers, including Google, Microsoft, and Azure, but AWS offers a particularly strong ecosystem for the types of companies we support.

For example, AWS provides technologies such as Amazon SageMaker and Amazon Bedrock, which can support machine learning, artificial intelligence development, and model training.

These capabilities are increasingly important for biotechnology companies that rely on computational science, large datasets, and sophisticated research workflows.

However, what makes our partnership particularly valuable is the funding support we can help eligible companies access through AWS.

We work with startups at different stages, from companies seeking seed investment to businesses progressing through Series A, B, and C funding rounds.

ACCELERATING BIOTECH INNOVATION: HOW PTP HELPS LIFE SCIENCES STARTUPS BUILD SECURE AI INFRASTRUCTURE, ACCESS CLOUD FUNDING, AND SCALE TOWARD IPO

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER

INTERVIEW BY SHOTA BAGATURIA | OCTOBER 16, 2026

Through our partnership, we can often help these companies secure AWS funding or credits that significantly reduce the cost of moving their technology platforms into the cloud.

In many cases, we're able to help them migrate their infrastructure and prepare it for production with little or virtually no initial cost, depending on the funding available.

That's a tremendous advantage for startups because it allows them to preserve financial resources while building the technology foundation they need to grow.

Wall St New York Magazine: You mentioned that you sometimes describe your role as being similar to that of a venture capitalist. What do you mean by that, and how does your work contribute to the growth of emerging biotechnology companies?

Ron: I like to think of myself as a kind of mini venture capitalist, although my role is different from that of a traditional financial investor.

Because of our relationship with AWS, I have the opportunity to meet biotechnology startups, understand their technology requirements, and identify opportunities where we can help them access resources and accelerate their development.

A lot of these companies have incredible scientific ideas and innovative technologies, but they may not have the infrastructure, technical expertise, or financial resources necessary to bring those ideas into production.

That's where we can make a meaningful difference.

We can help them access AWS funding, establish their cloud infrastructure, develop secure environments, and build the systems they need to support their research and operations.

From my perspective, it's about identifying promising companies and helping them overcome technological and financial barriers.

As those companies grow, we grow alongside them.

We can support them from their earliest stages through multiple funding rounds, commercial development, and potentially all the way to an initial public offering.

Of course, by the time a company reaches that stage, it may have developed its own internal technology team. But even then, there's still an opportunity for us to continue providing specialized services and support.

Wall St New York Magazine: Security and regulatory compliance are particularly important in healthcare and pharmaceuticals. How does PTP help biotechnology companies establish infrastructure that meets industry requirements?

Ron: Security and compliance are absolutely essential in the biotechnology and life sciences industries.

ACCELERATING BIOTECH INNOVATION: HOW PTP HELPS LIFE SCIENCES STARTUPS BUILD SECURE AI INFRASTRUCTURE, ACCESS CLOUD FUNDING, AND SCALE TOWARD IPO

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER

INTERVIEW BY SHOTA BAGATURIA | OCTOBER 16, 2026

Investors, pharmaceutical partners, and other stakeholders want to know that a company has the technological infrastructure necessary to operate securely and scale responsibly.

When we work with startups, we're not simply moving their systems into the cloud. We're helping them build environments designed around the requirements of healthcare and life sciences.

That includes supporting infrastructure aligned with regulatory frameworks such as 21 CFR Part 11 and GxP requirements.

These standards are particularly relevant for companies working with regulated research processes, electronic records, and pharmaceutical development.

Our objective is to establish a secure and scalable environment so companies can grow without constantly worrying about whether their infrastructure can support their next stage of development.

Startups need to be agile. They need the flexibility to expand their computing capabilities, adapt their workflows, and respond to new opportunities.

We help provide that flexibility while addressing the security and regulatory considerations that are so important in this industry.

Wall St New York Magazine: Artificial intelligence and computational biology are becoming increasingly important in pharmaceutical research. How does PTP support companies working with advanced scientific data and AI-driven research?

Ron: This is an area where our technical capabilities and life sciences specialization come together.

We have a team that includes scientists, engineers, and technology specialists who understand the requirements of biotechnology research.

For companies working in bioinformatics, multiomics, and computational science, we can help optimize their workflows and establish the computing environments necessary to support complex analysis.

That might involve improving the way they process biological data, developing infrastructure for machine learning, or supporting AI applications using cloud-based technologies.

AWS tools such as SageMaker and Bedrock can provide important capabilities for companies developing machine learning and artificial intelligence solutions.

But our work extends beyond AI.

We can also help companies with fundamental IT operations, cybersecurity, infrastructure management, and technical protocols.

The range of services is quite broad, but our focus remains on the needs of life sciences organizations.

ACCELERATING BIOTECH INNOVATION: HOW PTP HELPS LIFE SCIENCES STARTUPS BUILD SECURE AI INFRASTRUCTURE, ACCESS CLOUD FUNDING, AND SCALE TOWARD IPO

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER

INTERVIEW BY SHOTA BAGATURIA | OCTOBER 16, 2026

We want scientists and biotechnology entrepreneurs to spend more time advancing their research and less time managing technological obstacles.

Wall St New York Magazine: What makes PTP's approach particularly valuable for early-stage companies seeking investment or preparing for larger funding rounds?

Ron: One of the biggest advantages is that we understand what growing biotechnology companies need at different stages of their development.

A small startup may initially need help establishing basic cloud infrastructure, managing research data, or securing its IT environment.

As that company progresses toward seed funding or a Series A investment, its requirements become more sophisticated.

Investors want to see that the business has a scalable technology foundation and can support its growth plans.

Later, as the company advances toward Series B, Series C, or commercial production, its infrastructure needs may expand significantly.

Our role is to help companies build an environment that can evolve with them.

Because we can also help eligible companies access AWS funding, we're able to reduce some of the financial burden associated with building that infrastructure.

For a young biotechnology company, that can make a substantial difference.

Rather than spending a significant portion of its early capital on technology infrastructure, the company may be able to direct more resources toward research, product development, and other essential business activities.

Wall St New York Magazine: PTP is participating in the Medical Innovation Olympics. What attracted you to this initiative, and what opportunities do you see for collaboration with participating biotechnology companies?

Ron: We're really excited to be part of the Medical Innovation Olympics.

For me, one of the most valuable aspects of this event is the opportunity to learn about the innovative startups and technologies being developed across the healthcare and biotechnology sectors.

There are so many companies working on significant scientific and medical challenges, and it's exciting to hear about their ideas and progress.

My goal is to identify companies that we might be able to support.

Some may need help accessing AWS funding. Others may require cloud migration, AI infrastructure, bioinformatics optimization, or security services.

ACCELERATING BIOTECH INNOVATION: HOW PTP HELPS LIFE SCIENCES STARTUPS BUILD SECURE AI INFRASTRUCTURE, ACCESS CLOUD FUNDING, AND SCALE TOWARD IPO

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER

INTERVIEW BY SHOTA BAGATURIA | OCTOBER 16, 2026

Because our team includes scientists, engineers, and IT specialists, we can provide support across a wide range of technological requirements.

We're also working with Tim and Amedea to explore how we can help develop their platform, migrate more of its infrastructure to AWS, and establish a more secure and integrated environment.

The platform currently has some fragmented components, and we see an opportunity to help bring those elements together into a more cohesive infrastructure.

We're excited about the possibility of growing alongside Amedea and supporting the broader innovation ecosystem connected to this initiative.

Wall St New York Magazine: Where is Pinnacle Technology Partners based, and how is your organization structured to support clients internationally?

Ron: I'm personally based in Chicago, while Pinnacle Technology Partners is generally considered to be based in Boston.

However, we're really a distributed organization, with people working remotely across different locations.

We have more than 250 employees across the United States and India.

That structure gives us access to a broad range of technical expertise and allows us to support clients with different operational requirements.

We have specialists in infrastructure, engineering, science, security, and other areas of technology.

Our distributed workforce is particularly useful because the companies we work with often require a combination of different technical capabilities.

Whether we're supporting a biotechnology startup or a larger pharmaceutical organization, we can bring together the appropriate expertise to address its needs.

Wall St New York Magazine: Finally, what is your long-term vision for PTP's role in the biotechnology industry, and what message would you share with startups seeking to accelerate their growth?

Ron: Our objective is to continue helping biotechnology and life sciences companies get off the ground and scale successfully.

There are so many promising startups developing technologies that could make a real difference in healthcare and scientific research.

But building a successful biotechnology company requires more than a great scientific idea.

You also need reliable infrastructure, strong security, access to computing resources, and the ability to scale as your business develops.

That's where we want to help.

ACCELERATING BIOTECH INNOVATION: HOW PTP HELPS LIFE SCIENCES STARTUPS BUILD SECURE AI INFRASTRUCTURE, ACCESS CLOUD FUNDING, AND SCALE TOWARD IPO

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER

INTERVIEW BY SHOTA BAGATURIA | OCTOBER 16, 2026

Through our technology partnerships, technical expertise, and access to potential AWS funding support, we can help companies overcome some of those challenges.

We want to be a long-term partner that supports businesses from their earliest stages through growth, production, and potentially an IPO.

The Medical Innovation Olympics has been a fantastic opportunity to meet innovative companies and learn about the work they're doing.

We're very grateful to be here, and I'm excited to see how we can help some of these businesses move forward.

Wall St New York Magazine: Thank you, Ron, for sharing your insights into the role of cloud infrastructure, artificial intelligence, and technology partnerships in accelerating biotechnology innovation. We wish Pinnacle Technology Partners continued success and look forward to seeing its collaborations with emerging life sciences companies.

Ron: Thank you so much for having us. It's been a great experience, and we really appreciate the invitation.

WALL ST

EXCLUSIVE INTERVIEW WITH RON OF PINNACLE TECHNOLOGY PARTNERS (PTP)

MEDICAL INNOVATION OLYMPICS



CLICK QR OR SCAN TO WATCH

NEW YORK

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005

BEST PRACTICES
Access. Intelligence. Excellence

BEST PRACTICES, LLC: DRIVING EXCELLENCE AND INNOVATION IN THE MEDICAL DEVICE INDUSTRY

In an era of rapid technological advancement, increasing regulatory complexity, and growing demand for innovative healthcare solutions, medical device companies face unprecedented opportunities and challenges. From groundbreaking diagnostic technologies to sophisticated surgical equipment, the industry continues to transform modern medicine. Yet successful innovation requires more than technological breakthroughs. It demands strategic leadership, operational efficiency, market intelligence, and the ability to translate promising ideas into commercially successful products.

Best Practices, LLC, a research, benchmarking, and strategic advisory firm, is helping healthcare and medical device companies navigate this increasingly competitive environment by providing the intelligence, analytical tools, and organizational insights necessary to achieve sustainable growth. Through its specialized research and consulting services, the company supports executives in identifying performance gaps, evaluating competitive positioning, improving organizational structures, and implementing proven business practices. Its approach combines industry-specific expertise with cross-industry benchmarking, enabling organizations to learn from successful companies and apply those insights to their own operations.

Transforming Data Into Competitive Advantage

At the center of Best Practices, LLC's business philosophy is a powerful principle: organizations achieve stronger results when strategic decisions are informed by reliable research and measurable performance indicators.



BEST PRACTICES
Access. Intelligence. Excellence

BEST PRACTICES, LLC: DRIVING EXCELLENCE AND INNOVATION IN THE MEDICAL DEVICE INDUSTRY

company's benchmarking services examine critical business functions, including leadership, organizational strategy, investment economics, workforce capabilities, technological innovation, productivity, and operational quality.

By comparing internal performance against established industry benchmarks, medical device manufacturers can identify inefficiencies, strengthen decision-making, and allocate resources more effectively.

This research-driven approach is particularly valuable in an industry where product development involves significant capital investment, demanding regulatory requirements, and complex commercialization strategies.
Rather than relying exclusively on internal experience, executives can use external benchmarks to evaluate whether their organizations are operating efficiently and where meaningful improvements can be achieved.

Supporting Medical Innovation and Commercialization

Best Practices, LLC provides expertise across several essential functions of the medical device business, including clinical operations, medical affairs, regulatory compliance, brand management, sales leadership, competitive intelligence, market research, and financial forecasting.
These capabilities address challenges throughout the commercial lifecycle of medical technologies, from early development and clinical evaluation to market introduction and long-term product management.


The firm's services include customized research and consulting, industry benchmarking reports, advisory programs, and access to a specialized best-practices database containing performance metrics, operational insights, and case studies.

For emerging medical technology companies, such intelligence can help inform product launch strategies and organizational planning. For established manufacturers, it can support efforts to improve productivity, strengthen commercial operations, and maintain competitiveness in evolving healthcare markets.

BEST PRACTICES
Access. Intelligence. Excellence

BEST PRACTICES, LLC: DRIVING EXCELLENCE AND INNOVATION IN THE MEDICAL DEVICE INDUSTRY

Leadership Built on Industry Experience
An important figure behind the company's approach is Christopher Bogan, Founder and Partner of Best Practices, LLC, whose professional background includes approximately three decades of experience helping American companies bring new biopharmaceutical products to market.



According to the company, Bogan has contributed to the commercialization of numerous pharmaceutical brands representing substantial market value. His experience reflects the importance of combining scientific innovation with disciplined commercial execution.
Under this research-oriented philosophy, Best Practices, LLC emphasizes that successful healthcare businesses must integrate technological excellence with effective management, competitive intelligence, and evidence-based strategic planning.

Building the Future of Healthcare Excellence
As artificial intelligence, digital healthcare, advanced diagnostics, and increasingly sophisticated medical devices reshape the global healthcare landscape, companies must continually reassess their business strategies and operating models.

Best Practices, LLC operates at the intersection of innovation and organizational performance, helping medical technology leaders understand how successful companies structure operations, manage resources, and compete in complex markets.

Its work illustrates a broader lesson for the healthcare industry: scientific discovery creates opportunity, but strong management and informed strategic decisions help transform that opportunity into lasting business success.

PEACCEL
EXPLORE MORE.BETTER.FASTER

PEACCEL AIMS TO LEAD QUANTUM AI DRUG DISCOVERY

WALL ST NEW YORK MAGAZINE
EDITORIAL BOARD | OCTOBER 16, 2026

Cardiovascular diseases claim a life about every 1.6 seconds worldwide, based on WHO's 2022 estimate. For patients with uncontrolled cholesterol or resistant infections, better medicines are urgent. Developing them starts with a difficult choice: which molecule deserves the next experiment?

PEACCEL (Paris, FR) develops innov'SAR, an AI platform for target identification and peptide design and optimisation. It helps pharma and biotech teams select promising candidates for testing across activity, safety, stability and developability. Its Quantum roadmap targets difficult learning and optimisation tasks, building on AI methods supported by experimental and industrial evidence.

The company has drug candidates in early preclinical development: a cardiovascular bispecific peptide with a novel mechanism of action, and an antimicrobial peptide portfolio for serious infections. For the antimicrobial programme, PEACCEL computationally screened 636 million peptides to identify leads for experimental development.

Founder Dr Frédéric Cadet brings expertise in biochemistry, AI and Quantum computing. US-based strategic partner Jacob Weintraub, Esq., combines a graduate degree in organic chemistry, experience with major pharmaceutical and hi-tech companies and expertise in patents and licensing. The wider team covers pharmaceutical business development, finance and specialist scientific advice. PEACCEL's commercial model combines discovery partnerships, platform access and therapeutic licensing. Its Quantum layer is designed to make the platform harder to copy as biological search becomes increasingly computational.



DR. FRÉDÉRIC CADET

Dr Frédéric Cadet, founder of PEACCEL, alongside research on Quantum protein folding at Quantum Week Toronto. PEACCEL's ambition is to lead Quantum AI drug discovery by combining validated AI with selective Quantum computing.

PEACCEL: WHERE BIOTECHNOLOGY, ARTIFICIAL INTELLIGENCE, AND QUANTUM RESEARCH CONVERGE

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER

INTERVIEW BY SHOTA BAGATURIA | OCTOBER 16, 2026

Wall Street New York Magazine: Dr. Cadet, please tell us about yourself, your background in biotechnology and pharmaceutical innovation, and what led you to create PEACCEL.

Dr. Frédéric Cadet: My background is in biochemistry, protein engineering, and machine learning. Throughout my career, I have focused on connecting molecular measurements with computational models that help researchers understand and improve biological molecules.

Our previous projects have included work for a U.S. Food and Drug Administration laboratory and pharmaceutical companies. These experiences reinforced my conviction that scientific discovery becomes more valuable when it translates into better decisions.

I founded PEACCEL to bridge that gap. Our objective is to help pharmaceutical teams identify promising molecular candidates, understand their strengths and limitations, and select the experiments most likely to move a development program forward.

Ultimately, we want to make drug discovery more informed, efficient, and measurable.

Wall Street New York Magazine: PEACCEL's SAR decision platform is central to this vision. How does the technology work, and how does it help researchers determine which molecules should advance to laboratory testing?

Dr. Frédéric Cadet: Our innov'SAR platform is designed to support decisions throughout the early stages of molecular discovery.

A research team provides molecular sequences, available assay data, and a defined objective. The platform then supports target identification, candidate design and evaluation, and the prioritization of molecules across multiple properties.

Rather than simply generating a list of predicted candidates, innov'SAR provides researchers with a prioritized shortlist, explanations of the results, estimates of uncertainty, and recommendations for the next experiments.

This distinction is important. In pharmaceutical research, a prediction is only useful if it helps determine what to do next.

Our objective is to help teams focus their laboratory resources on the candidates and experiments most likely to produce meaningful information. With suitable data, we aim to deliver an initial shortlist within one to three weeks.

We also encourage pharmaceutical companies to benchmark our approach against their existing workflows using the same candidates, assays, and acceptance criteria. The evaluation should measure candidate quality, experimental requirements, time, and cost.

For us, the ultimate test is measurable performance in a real research environment.

Wall Street New York Magazine: PEACCEL is also conducting research into quantum computing and its potential applications in drug discovery. What progress have you made, and how do you see quantum methods complementing classical artificial intelligence?



JACOB G. WEINTRAUB, ESQ

Our strategic partner based in Boston, MA (USA) Jacob G. Weintraub, Esq. guides PEACCEL as an international strategic advisor in licensing and intellectual property.

PEACCEL: WHERE BIOTECHNOLOGY, ARTIFICIAL INTELLIGENCE, AND QUANTUM RESEARCH CONVERGE

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER

INTERVIEW BY SHOTA BAGATURIA | OCTOBER 16, 2026

Dr. Frédéric Cadet: We believe quantum methods deserve rigorous investigation as potential complements to classical computational approaches.

Our research includes peptide-safety classification and a quantum autoencoder trained numerically on three million peptide sequences. In one hemolysis benchmark, our quantum simulation achieved an accuracy of 74.26%, compared with 72.28% for the reference approach.

That is an encouraging research result, but we must interpret it carefully. An improvement on a particular benchmark does not, by itself, establish a general quantum advantage or demonstrate superior performance in pharmaceutical development.

Our team has produced ten papers and preprints related to quantum research since November 2024. This body of work reflects our commitment to exploring where quantum-inspired and quantum-computing methods may contribute to molecular modeling.

Our strategy is selective rather than ideological. We are not seeking to replace classical AI simply because quantum technology is emerging. We want to determine where quantum methods can deliver measurable value beyond strong classical baselines.

Every module must demonstrate its usefulness through rigorous benchmarking before we consider it for deployment.

Wall Street New York Magazine: PEACCEL evaluates biological activity, safety, stability, and developability. Why is it important to assess these characteristics together rather than focusing primarily on biological activity?

Dr. Frédéric Cadet: Biological activity is essential, but it is only one part of the equation.

A peptide may perform exceptionally well in a laboratory assay yet degrade too quickly, damage cells, or present significant formulation challenges. A molecule can be scientifically interesting without being a viable therapeutic candidate.

The more important question is whether the molecule can reach its intended target, remain sufficiently stable, produce the desired biological effect, and do so at a tolerable exposure.

By evaluating these characteristics together, we aim to identify potential obstacles earlier in the discovery process. This can help researchers prioritize candidates more intelligently and avoid investing too heavily in molecules whose limitations might otherwise emerge later.

Our cardiovascular program illustrates both the promise and the discipline required in this field. We have observed encouraging results in human-cell experiments, but these findings represent an early stage of development. Further studies of exposure, organ safety, and efficacy are necessary before we can determine whether the program merits advancement.

We believe responsible innovation requires scientific ambition accompanied by transparent evidence and clearly defined development milestones.

PEACCEL: WHERE BIOTECHNOLOGY, ARTIFICIAL INTELLIGENCE, AND QUANTUM RESEARCH CONVERGE

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER

INTERVIEW BY SHOTA BAGATURIA | OCTOBER 16, 2026

Wall Street New York Magazine: Your platform draws on a database of approximately 4 million peptides, the molecular building blocks of proteins and important biological messengers. The collection includes approximately 100,000 experimentally labeled peptides and 3.9 million annotated sequences. How does the scale and quality of this database contribute to PEACCEL's competitive position?

Dr. Frédéric Cadet: Data quality and diversity are fundamental to the performance of molecular AI.


Our collection combines approximately 100,000 experimentally labeled peptides with 3.9 million annotated sequences. These two categories serve complementary purposes.

Experimental labels provide evidence about measured molecular behavior. The broader collection helps us explore molecular diversity, identify patterns, and investigate candidate sequences beyond those represented in the experimentally characterized dataset.

However, scale alone does not guarantee predictive performance. We must distinguish experimentally measured properties from computational annotations, account for data limitations, and evaluate our models on relevant datasets.

We are encouraged by results supporting the broader methodology behind innov'SAR. In a 2025 *Nature Communications* study, an independently applied approach reportedly improved activity for all eight top-ranked enzyme variants. In a separate company-reported industrial application involving neurotransmitter production, enzyme activity improved by 56% relative to the original enzyme.

These findings provide useful evidence for our underlying approach, although they do not independently validate every application of our platform. Each new therapeutic target, molecular class, and development program requires its own assessment.




PEACCEL: WHERE BIOTECHNOLOGY, ARTIFICIAL INTELLIGENCE, AND QUANTUM RESEARCH CONVERGE

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER

INTERVIEW BY SHOTA BAGATURIA I OCTOBER 16, 2026



Our ambition is to combine a strong data foundation with rigorous validation and increasingly sophisticated computational methods.

Wall Street New York Magazine: Jacob, PEACCEL is building a technology platform that combines proprietary data, AI, biotechnology, and quantum research. How do you see the company's intellectual property supporting its long-term commercial strategy?

Jacob Weintraub, Esq.: PEACCEL's intellectual property strategy encompasses more than 30 patents, alongside proprietary data, technical know-how, and the capabilities embedded in its platform.

In a technology-driven pharmaceutical business, defensibility does not depend on patents alone. It also depends on the quality of the underlying science, the uniqueness of the data, the reproducibility of the results, and the ability to translate technical capabilities into commercial value.

Our established classical AI capabilities provide an important foundation. As our quantum modules demonstrate measurable advantages over those methods, they may create additional differentiation and strengthen the platform's strategic position.

My background in chemistry and experience working with major pharmaceutical companies help me approach these innovations from both a scientific and commercial perspective.

We are focused on translating PEACCEL's capabilities into practical licensing arrangements, research collaborations, and strategic partnerships. The objective is to build a business model in which demonstrable scientific value supports sustainable commercial relationships.

PEACCEL: WHERE BIOTECHNOLOGY, ARTIFICIAL INTELLIGENCE, AND QUANTUM RESEARCH CONVERGE

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER

INTERVIEW BY SHOTA BAGATURIA | OCTOBER 16, 2026

Wall Street New York Magazine: Where do you see PEACCEL in five to seven years, and what are the major milestones required to achieve that vision?

Dr. Frédéric Cadet: Our ambition is to establish PEACCEL as the leader in quantum-enabled AI for drug discovery.

We believe the next generation of computational drug discovery platforms will combine validated classical AI with selective quantum capabilities, applying each where it can deliver the greatest practical benefit.

Over the next 24 months, our priorities are to strengthen customer validation, advance preclinical evidence for our two lead programs, and demonstrate the value of our quantum research through clearly defined benchmarks.

We are seeking to raise $50 million in Series A. The financing would support these technical and commercial milestones and help position the company for a subsequent stage of growth.

Within five years, we aim to establish a widely used computational drug discovery platform, develop recurring relationships with pharmaceutical partners, and advance proprietary drug candidates toward clinical development.

Our commercial strategy combines discovery partnerships, platform licensing, and the potential out-licensing of therapeutic assets. These complementary opportunities could allow us to generate value from both our technology and the drug candidates it helps develop.

The five-to-seven-year horizon is an opportunity to build a business around measurable scientific progress rather than technology promises alone.

Ultimately, our success should be judged by the quality of the molecules we discover, the strength of the evidence supporting them, and their potential to become better treatment options for patients.

Wall Street New York Magazine: What would you most like pharmaceutical executives, investors, and research leaders to understand about PEACCEL today?

Dr. Frédéric Cadet: We want them to understand that our objective is not simply to build another AI platform or to associate ourselves with the promise of quantum computing.

We are building a decision-making capability for pharmaceutical research, grounded in molecular science, supported by data, and evaluated through measurable outcomes.

We invite pharmaceutical teams to test our platform against their existing processes, using agreed experimental criteria and transparent comparisons. We also welcome partners who share our interest in determining where emerging computational methods can make a meaningful difference.

The opportunity is significant, but credibility must be earned through evidence. That principle will continue to guide PEACCEL as we develop our technology, advance our programs, and build long-term partnerships.

EMPOWERING THE HUMAN SIDE OF ARTIFICIAL INTELLIGENCE: HOW ATHENI IS HELPING ORGANIZATIONS TURN AI INVESTMENT INTO REAL-WORLD CAPABILITY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD I OCTOBER 16, 2026

Exclusive Interview with Mackenzie Howe, Co-Founder of Atheni

Interview by Shota Bagaturia | Wall St New York Magazine

As artificial intelligence rapidly transforms industries worldwide, businesses are facing a challenge that extends beyond acquiring sophisticated technology: ensuring their employees have the knowledge, confidence, and practical skills to use it effectively.

Atheni.ai, co-founded by Mackenzie Howe, is addressing this challenge by focusing on the human side of AI adoption. Through its AI enablement accelerator, the company helps organizations develop workforce capabilities, identify relevant applications, and integrate artificial intelligence into everyday operations while respecting industry-specific regulatory requirements.

In an exclusive interview with Wall St New York Magazine, Howe discusses the origins of Atheni, company's evolution from consultancy to technology platform, its international expansion, and its mission to make artificial intelligence genuinely useful for people across industries.

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005

EMPOWERING THE HUMAN SIDE OF ARTIFICIAL INTELLIGENCE: HOW ATHENI IS HELPING ORGANIZATIONS TURN AI INVESTMENT INTO REAL-WORLD CAPABILITY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD | OCTOBER 16, 2026

Wall St New York Magazine: Please tell us about yourself and your company, Atheni.ai. How did the idea originate, and what inspired its name?

Mackenzie Howe: I'm the co-founder of Atheni.ai, a company focused on helping organizations and their employees use artificial intelligence more effectively.

The story behind our name is actually quite interesting. We came up with Atheni.ai while I was running the Athens Marathon. At the time, it simply seemed like the right name for what we were building.

Interestingly, as our company developed, artificial intelligence became central to our work. The name ended up being particularly fitting because of the connection between Athens and AI.

Our focus today is on something that I believe is fundamental to the successful adoption of artificial intelligence: human enablement. We help organizations ensure that their people can actually benefit from the technology they're investing in.

Wall St New York Magazine: Artificial intelligence is attracting substantial investment worldwide. What specific problem is Atheni.ai trying to solve?

Mackenzie Howe: We focus on what happens after a company acquires AI technology.

Organizations are investing in increasingly sophisticated tools, but purchasing technology is only one part of the process. The real challenge is making sure employees understand how to use those tools effectively within their actual jobs.

That's where human enablement becomes so important.

We initially started as a consultancy, helping organizations navigate this challenge. Over time, we developed a platform designed to accelerate AI capability across teams.

Our objective is to bridge the gap between an organization's AI ambitions and the practical ability of its employees to implement those ambitions in their everyday work.

Wall St New York Magazine: How does your AI enablement accelerator work, and what makes it different from traditional AI training programs?

Mackenzie Howe: One of the most important differences is that our approach is highly personalized.

Traditional training programs often teach generic AI skills. While those skills can be useful, they don't necessarily help someone understand exactly how artificial intelligence can improve their particular workflow.

Our platform focuses on building AI capability within teams by tailoring the learning experience to each individual's role, industry, and specific responsibilities.

We identify the skills people actually need and provide relevant use cases for the technologies available to them.

EMPOWERING THE HUMAN SIDE OF ARTIFICIAL INTELLIGENCE: HOW ATHENI IS HELPING ORGANIZATIONS TURN AI INVESTMENT INTO REAL-WORLD CAPABILITY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD | OCTOBER 16, 2026

For example, the way someone working in financial services might use AI can be very different from how someone in manufacturing, education, or healthcare would use it.

Our accelerator takes those differences into account.

It also considers the constraints within each organization, helping employees understand not only what AI can do but also how they can use it appropriately within their working environment.

Ultimately, we want every individual to receive the specific support they need to become more capable and confident in using AI.

Wall St New York Magazine: You work with organizations in highly regulated industries, including financial services and pharmaceuticals. How do you address the challenges associated with AI adoption in these sectors?

Mackenzie Howe: This is a very important part of our approach.

In industries such as financial services, pharmaceuticals, and healthcare, organizations operate within very specific regulatory and operational constraints.

You can't simply introduce an AI tool and expect everyone to use it in the same way.

There are restrictions, internal policies, and industry requirements that determine how technologies can be applied within particular workflows.

Our accelerator filters relevant AI use cases through those organizational constraints.

This means that employees receive guidance that is not only tailored to their responsibilities but also aligned with the environment in which they operate.

If a company has established a particular AI strategy, our role is to help translate that strategy into practical applications for individuals throughout the organization.

The goal is to make AI adoption effective while respecting the requirements of each business and industry.

Wall St New York Magazine: Your professional background is in financial services. How did that experience influence the development of Atheni.ai, and which industries did you initially target?

Mackenzie Howe: My background is in financial services, so that was naturally where we started.

Our initial work focused on professional services organizations, including banks, law firms, and asset managers.

These industries provided a strong starting point because they are highly knowledge-intensive and operate in environments where technology adoption must be approached carefully.

EMPOWERING THE HUMAN SIDE OF ARTIFICIAL INTELLIGENCE: HOW ATHENI IS HELPING ORGANIZATIONS TURN AI INVESTMENT INTO REAL-WORLD CAPABILITY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD I OCTOBER 16, 2026

However, as we developed the business, we realized that the challenges we were addressing were not unique to financial services.

They were actually global, industry-wide challenges.

Organizations everywhere were asking essentially the same question: How do we use artificial intelligence effectively?

That realization helped shape the evolution of Atheni.ai and encouraged us to expand into other industries and markets.

Wall St New York Magazine: Atheni.ai has already developed an international client base. Could you tell us about your global expansion and the types of organizations you currently serve?

Mackenzie Howe: We've been fortunate to work with organizations across a wide range of industries and geographical markets.

Our clients extend across the United States, Europe, Finland, and the Middle East.

We've also expanded well beyond our original focus on financial and professional services.

Today, our work includes manufacturing, engineering, education, pharmaceuticals, healthcare, government, and the public sector.

What's interesting is that, despite the differences between these industries, the underlying challenge is remarkably similar.

Everyone is trying to understand how to make AI genuinely useful within their organizations.

The technologies may differ, the workflows may differ, and the regulatory environments may differ, but the need to develop human capabilities remains consistent.

That's why we believe our approach can be applied across so many sectors.

Wall St New York Magazine: At what stage is Atheni.ai in its development, and how has the company financed its growth?

Mackenzie Howe: We raised a small pre-seed funding round last year, which supported the early development of our business.

We began as a consultancy, working directly with organizations to understand their challenges around AI adoption and employee enablement.

Since then, we've evolved to develop our own platform, which serves as a human enablement accelerator.

That evolution has allowed us to move beyond providing consultancy services alone and offer organizations a more structured way to build AI capability across their teams.

Our focus continues to be on helping companies make the transition from simply having AI technology to using it effectively throughout their organizations.

EMPOWERING THE HUMAN SIDE OF ARTIFICIAL INTELLIGENCE: HOW ATHENI IS HELPING ORGANIZATIONS TURN AI INVESTMENT INTO REAL-WORLD CAPABILITY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD | OCTOBER 16, 2026

Wall St New York Magazine: Finally, what do you believe is the most important factor determining whether companies will succeed in adopting artificial intelligence?

Mackenzie Howe: I think the key is recognizing that AI adoption is fundamentally about people as well as technology.

Companies can invest in powerful AI systems, but the real value comes when employees understand how those systems can help them perform their roles more effectively.

That requires relevant skills, practical use cases, and support tailored to individual responsibilities.

It also requires organizations to think carefully about their own operating environments and constraints.

Our mission at Atheni.ai is to make sure that an organization's AI strategy reaches every individual who needs to implement it.

If we can help people develop the right capabilities and understand how to apply AI meaningfully within their work, then organizations will be much better positioned to benefit from their technology investments.

Wall St New York Magazine: Thank you, Mackenzie, for sharing the story behind Atheni.ai and your perspective on the future of artificial intelligence adoption. Congratulations on your company's progress and international expansion.

Mackenzie Howe: Thank you very much. It's been a pleasure.

WALL ST

EXCLUSIVE INTERVIEW WITH MACKENZIE HOWE, CO-FOUNDER OF ATHENI

MEDICAL INNOVATION OLYMPICS



CLICK QR OR SCAN TO WATCH

NEW YORK

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005

RAISING THE STANDARD FOR WOMEN'S HEALTH PRODUCTS: HOW INANNA CERTIFICATIONS IS BRINGING INDEPENDENT TESTING, TRANSPARENCY, AND CONSUMER CONFIDENCE TO THE WELLNESS INDUSTRY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD | OCTOBER 16, 2026

Inanna Certifications: Building Trust in Women's Health Products

Inanna Certifications is developing an independent, science-informed certification program for products marketed to women. Led by Shaylee Meyer and Sam Kinne, Inanna aims to give consumers clearer information about product quality while helping brands demonstrate their commitment to rigorous testing and transparency. The certification framework combines independent laboratory testing with criteria informed by published research, recognized safety thresholds, and women's life stages. Its approach considers how products are actually used, including frequency, duration, and route of exposure, to guide the evaluation of contaminants and other measurable product characteristics. Scientific review supports the development of defined, product-specific certification criteria. The proposed offering brings together testing, expert evaluation, and a recognizable Inanna Certified mark for qualifying products, supported by ongoing surveillance and annual renewal. For consumers, the mark is intended to make independently evaluated products easier to identify. For participating brands, it provides a way to communicate that their products meet defined standards specific to women's anatomy and health through third-party verification. Through its participation in the 2026 Medical Innovation Olympics, Inanna presented a vision for making women's health considerations a more deliberate part of product evaluation. Its mission is to translate scientific evidence into practical certification standards that support informed purchasing decisions, strengthen accountability, and give brands committed to the women they serve a competitive edge.

RAISING THE STANDARD FOR WOMEN'S HEALTH PRODUCTS: HOW INANNA CERTIFICATIONS IS BRINGING INDEPENDENT TESTING, TRANSPARENCY, AND CONSUMER CONFIDENCE TO THE WELLNESS INDUSTRY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD | OCTOBER 16, 2026

Wall St New York Magazine: Please tell us about yourself, your professional background, and what inspired you to establish INANNA CERTIFICATIONS.

Shaylee Meyer: My name is Shaylee Meyer, and I'm the founder and CEO of INANNA CERTIFICATIONS.

INANNA CERTIFICATIONS is a third-party certification label specifically designed for products marketed toward women.

Our primary focus right now is on categories such as nutritional supplements and skincare, although our certification model has the potential to expand into additional product categories in the future.

What we're really trying to accomplish is to create a meaningful distinction between companies that are genuinely committed to product quality and those whose products may not meet the same standards.

There are brands that put tremendous care into what they're developing and selling to women. We want to give those companies a competitive advantage and help consumers recognize that commitment.

At the same time, we want women to feel more confident when they're shopping, whether they're purchasing products in a physical store or online.



SHAYLEE MEYER

RAISING THE STANDARD FOR WOMEN'S HEALTH PRODUCTS: HOW INANNA CERTIFICATIONS IS BRINGING INDEPENDENT TESTING, TRANSPARENCY, AND CONSUMER CONFIDENCE TO THE WELLNESS INDUSTRY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD I OCTOBER 16, 2026



INANNA CERTIFICATIONS

Our mission is to make it easier to identify high-quality products and support companies that are taking women's health seriously.

Wall St New York Magazine: The women's wellness and skincare markets offer consumers an enormous variety of products. What specific problem is INANNA CERTIFICATIONS seeking to solve?

Shaylee Meyer: One of the biggest challenges is that consumers often have difficulty determining which products are genuinely high quality.

There are so many products marketed toward women, and many of them are quite expensive.

People are spending significant amounts of money on supplements, skincare, and other wellness products, but they don't always have a reliable way to evaluate the quality of what they're purchasing.

That's really the problem we're trying to address.

We want to provide an independent certification label that helps women differentiate products that have undergone our testing process from those that haven't.

At the same time, we want to recognize the manufacturers that already care deeply about the quality of their products.

RAISING THE STANDARD FOR WOMEN'S HEALTH PRODUCTS: HOW INANNA CERTIFICATIONS IS BRINGING INDEPENDENT TESTING, TRANSPARENCY, AND CONSUMER CONFIDENCE TO THE WELLNESS INDUSTRY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD | OCTOBER 16, 2026

If a company is investing in producing something responsibly, we believe it should have an opportunity to demonstrate that commitment to consumers.

Our goal is to create more transparency and make product quality easier to recognize.

Wall St New York Magazine: How does your third-party certification process work, and what types of testing do you conduct?

Shaylee Meyer: The foundation of our certification model is independent product testing.

We work with laboratory partners that can physically test products for a range of quality and safety-related concerns.

That includes contaminants, adulteration, and other issues that may affect product integrity.

Our laboratory partners have broad testing capabilities, which allows us to evaluate different types of products depending on their composition and the concerns associated with that particular category.

For example, a nutritional supplement may require a different testing approach from a skincare product.

The important thing is that we're not simply relying on what a manufacturer says about its product.

We're looking to provide an additional level of independent evaluation.

That independent testing is what gives our certification model its purpose.

We want consumers to have a recognizable indicator that a product has been evaluated through our process, while also helping manufacturers demonstrate their commitment to quality.

Wall St New York Magazine: What makes INANNA CERTIFICATIONS different from traditional product labeling and manufacturer quality claims?

Shaylee Meyer: The key distinction is that we're a third-party certification organization.

When consumers look at products, they often see a lot of marketing language about quality, ingredients, and performance.

But it's not always easy to determine what those claims actually mean or how they have been verified.

Our approach is to create a certification label supported by independent testing.

We want women to be able to recognize that label and understand that the product has gone through an additional evaluation process.

That creates an opportunity for consumers to make more informed decisions.

It also creates an opportunity for brands.

If a company is already committed to making high-quality products, our certification can help distinguish it from competitors.

We're not trying to make the purchasing process more complicated. We're trying to make it easier for people to identify products that meet our standards.

Wall St New York Magazine: From a business perspective, how can independent certification create a competitive advantage for manufacturers in the women's health and wellness industries?

Shaylee Meyer: We believe certification can provide value to both consumers and manufacturers.

For manufacturers, the challenge is often communicating the quality of their products in a crowded marketplace.

There may be companies that are investing in better ingredients, more careful production processes, and stronger quality controls, but consumers don't necessarily have an easy way to recognize those efforts.

Our certification model is intended to help bridge that gap.

If a brand is already doing the right things and investing in product quality, we want to help elevate that brand.

A recognizable third-party label can give consumers another factor to consider when comparing products.

Ultimately, we want to create a marketplace where companies that genuinely care about women's health have an opportunity to stand out.

Wall St New York Magazine: Your company focuses specifically on products marketed toward women. Why is this specialization important to your business model?

Shaylee Meyer: Our focus is really about recognizing the needs of women as consumers and the enormous number of products being marketed specifically toward them.

Women are purchasing supplements, skincare, and wellness products for many different reasons, and these products can represent a significant financial investment.

We believe they deserve access to reliable information that helps them make better purchasing decisions.

By focusing specifically on products marketed toward women, we're able to develop a certification identity that speaks directly to this market.

At the same time, our mission is to support the brands that are genuinely committed to serving women with high-quality products.

RAISING THE STANDARD FOR WOMEN'S HEALTH PRODUCTS: HOW INANNA CERTIFICATIONS IS BRINGING INDEPENDENT TESTING, TRANSPARENCY, AND CONSUMER CONFIDENCE TO THE WELLNESS INDUSTRY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD | OCTOBER 16, 2026

We want to elevate those companies and make it easier for consumers to find them.

Wall St New York Magazine: INANNA CERTIFICATIONS participated in the Medical Innovation Olympics. How did that opportunity arise, and what was your experience competing alongside other healthcare and biotechnology innovators?

Shaylee Meyer: We were fortunate to receive an extended invitation to participate in the Medical Innovation Olympics.

Our business is somewhat adjacent to traditional medical innovation because we're focused on product certification and quality rather than directly developing medical treatments or technologies.

But we were extremely happy to be included.

It was a wonderful experience for us.

We participated in the preliminary round and then advanced to the second round.

Today, we're here to watch the other participants and enjoy the event.

It's been a lot of fun, and we've really appreciated the opportunity to be part of an initiative that brings together people working on different aspects of healthcare, wellness, and innovation.

Wall St New York Magazine: What value do you see in participating in events such as the Medical Innovation Olympics, particularly as an emerging company?

Shaylee Meyer: For us, participating has been a great experience.

Although our company operates in a slightly different area from some of the medical technology businesses here, there is still a strong connection through our focus on product quality and women's health.

It's exciting to be around other entrepreneurs and companies working to improve different aspects of healthcare and wellness.

We were very happy to have the opportunity to compete in the preliminary and second rounds.

Events like this also give emerging companies an opportunity to introduce their work to a broader audience and connect with people who are interested in innovation.

We're grateful to have been included.

Wall St New York Magazine: Where is INANNA CERTIFICATIONS headquartered, and how is your team organized?

Shaylee Meyer: Our headquarters is in Georgia, but we're a fully remote company.

That gives us the flexibility to work with people in different locations.

RAISING THE STANDARD FOR WOMEN'S HEALTH PRODUCTS: HOW INANNA CERTIFICATIONS IS BRINGING INDEPENDENT TESTING, TRANSPARENCY, AND CONSUMER CONFIDENCE TO THE WELLNESS INDUSTRY

MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD I OCTOBER 16, 2026

My partner, Sam Kenny, who is a very important part of our team, is based in Michigan.

So even though we're headquartered in Georgia, we're not limited to one physical location.

Our remote structure works well for the type of business we're building because our certification services aren't tied to a single geographic market.

We can work with companies in different locations and coordinate the necessary testing through our laboratory partners.

Wall St New York Magazine: Are you planning to expand into the New York market or other regions of the United States?

Shaylee Meyer: Absolutely. One of the advantages of our business model is that we can certify products from companies located almost anywhere.

We're not restricted to Georgia or the states where our team members live.

Right now, our primary focus is the United States, and we see opportunities to work with manufacturers and brands across the country.

That includes companies in markets such as New York.

Because our services are based on product evaluation and certification, we have the flexibility to support brands in different regions without needing a physical office in every location.

Our goal is to continue expanding our reach and helping more companies demonstrate their commitment to product quality.

Wall St New York Magazine: Looking ahead, do you envision INANNA CERTIFICATIONS becoming an international certification organization?

Shaylee Meyer: Yes, that's definitely something we'd love to pursue.

At the moment, we're primarily focused on the United States, but our long-term vision includes international expansion.

The challenges we're addressing aren't limited to American consumers.

Women around the world purchase supplements, skincare, and wellness products, and they face similar questions about quality and product integrity.

We believe there is potential for our certification model to serve a much broader market.

For now, we're focused on building the business and expanding our presence in the United

States, but international growth is certainly part of what we hope to achieve in the future.

Wall St New York Magazine: Finally, what message would you like to share with women purchasing wellness products and with manufacturers committed to producing high-quality products?

Shaylee Meyer: Our message is really about making quality more visible and accessible.

Consumers are paying a lot for products marketed toward their health and well-being, and we want to help them identify products that have undergone meaningful independent testing.

At the same time, we want manufacturers that genuinely care about product quality to receive recognition for their efforts.

Our goal is to elevate responsible brands and make it easier for women to differentiate between products when they're shopping.

Ultimately, we're trying to create a better experience for everyone involved by encouraging greater transparency and helping consumers access high-quality products.

That's what INANNA CERTIFICATIONS is all about.

Wall St New York Magazine: Thank you, Shaylee, for introducing us to INANNA CERTIFICATIONS and sharing your vision for improving transparency and product quality in the women's wellness industry. Congratulations on your participation in the Medical Innovation Olympics, and we wish you continued success as you expand your company.

Shaylee Meyer: Thank you so much. It's been a pleasure, and we really appreciate the opportunity.

RAISING THE STANDARD FOR WOMEN'S HEALTH PRODUCTS: HOW INANNA CERTIFICATIONS IS BRINGING INDEPENDENT TESTING, TRANSPARENCY, AND CONSUMER CONFIDENCE TO THE WELLNESS INDUSTRY
MEDICAL INNOVATION OLYMPICS

ROCKEFELLER CENTER
EDITORIAL BOARD I OCTOBER 16, 2026

Exclusive Interview with Shaylee Meyer, Founder and CEO of INANNA CERTIFICATIONS

Interview by Shota Bagaturia | Wall St New York Magazine

As the global wellness, skincare, and nutritional supplement industries continue to evolve, consumers are becoming increasingly concerned about product quality, ingredient integrity, and transparency. For women purchasing products specifically marketed toward their health and well-being, distinguishing between trustworthy brands and those making unsupported quality claims can be challenging.

INANNA CERTIFICATIONS, founded by entrepreneur Shaylee Meyer, is working to address this challenge through an independent, third-party product certification model designed for products marketed toward women.

By partnering with laboratories to test products for contaminants, adulteration, and other potential quality concerns, the company aims to give consumers greater confidence in their purchasing decisions while providing responsible manufacturers with an opportunity to distinguish themselves in a competitive marketplace.

During the Medical Innovation Olympics, Wall St New York Magazine spoke with Meyer about her company's mission, the importance of independent product testing, the challenges facing women's wellness brands, and her vision for expanding INANNA CERTIFICATIONS across the United States and eventually into international markets.

WALL ST

Inanna Certifications

EXCLUSIVE INTERVIEW WITH SHAYLEE MEYER, FOUNDER AND CEO OF INANNA CERTIFICATIONS

MEDICAL INNOVATION OLYMPICS



CLICK QR OR SCAN TO WATCH

NEW YORK

WALL ST NEW YORK MAGAZINE
40 WALL ST, FLOOR 28, NEW YORK, NY 10005

WALL ST NEW YORK MAGAZINE


CatchU: Transforming Fall Prevention Through Innovative Digital Health Technology

As the global population continues to age, preventing falls among older adults has become one of the most pressing challenges in modern healthcare. CatchU, an innovative digital health technology developed by JET Worldwide Enterprises Inc., is addressing this challenge through a scientifically grounded mobile application designed to identify fall risks before potentially devastating injuries occur.

Founded by neuroscientist Dr. Jeannette R. Mahoney, CatchU represents an important advancement in preventive healthcare by bringing sophisticated neurological and sensory assessments beyond traditional clinical environments. The company's mission is to help older adults maintain independence, improve mobility, and enjoy healthier, safer lives through early identification of fall-related risks.

Addressing a Major Healthcare Challenge

Falls represent one of the leading causes of injuries, hospitalizations, and loss of independence among older Americans. According to statistics highlighted by CatchU, nearly 30% of Americans aged 65 and older experience a fall annually, while millions require emergency medical treatment for fall-related injuries.



Beyond the physical consequences, falls create significant financial burdens for healthcare systems, families, and long-term care providers. Traditional assessments often depend on physical examinations, mobility tests, and clinical observations that may not fully capture the neurological and sensory factors contributing to instability.

CatchU introduces a different approach by examining how the brain processes and integrates sensory information, an essential component of maintaining balance and coordinating movement.

CATCHU ...BEFORE YOU FALL

WALL ST NEW YORK MAGAZINE

CatchU: Transforming Fall Prevention Through Innovative Digital Health Technology



Bringing Neuroscience Into Everyday Healthcare
At the center of CatchU's technology is a mobile assessment that measures reaction times and multisensory integration. The application evaluates how individuals respond to visual stimuli, tactile stimulation, and combinations of both.

These measurements provide quantitative information about sensory processing and motor responses, which researchers have associated with mobility and fall risk.

Unlike conventional laboratory-based assessments that require specialized equipment, CatchU is designed to be completed conveniently using a compatible mobile device. The assessment can take less than ten minutes, making it practical for use in homes, healthcare facilities, and senior living communities.
Results are provided to the ordering healthcare professional, helping inform discussions about preventive interventions, mobility improvement, and individualized care.

The underlying technology builds on years of neurological research, including studies supported by the National Institutes of Health and peer-reviewed investigations into the relationship between multisensory integration, aging, and mobility.

Scientific Leadership and Innovation
CatchU's development reflects the extensive scientific experience of Dr. Jeannette R. Mahoney, Professor of Neurology at Stony Brook University and Chief of the Division of Cognitive & Sensorimotor Aging.

With more than 15 years of research experience in multisensory integration, Dr. Mahoney has focused on understanding how age-related changes in sensory processing influence balance, mobility, and cognitive performance. Her research has also explored connections between multisensory functioning and neurological conditions, including Alzheimer's disease and Parkinsonian symptoms.
This scientific foundation distinguishes CatchU within the growing digital health industry, where the integration of validated research and accessible technology is increasingly important. The company reached a notable milestone in 2025 when CatchU received recognition through the National Institute on Aging Startup Challenge. Research published that year in Brain Sciences also demonstrated the technology's ability to capture multisensory integration phenomena comparable to those measured using laboratory equipment.

AliraHealth
Patient-Enabled Solutions™

WALL ST
NEW YORK
MAGAZINE

Alira Health: Bringing Patient Understanding to Healthcare Innovation

Helping life sciences companies navigate complex decisions, bring innovative therapies to market, and improve patients' lives.

Healthcare innovation is advancing rapidly. Scientific breakthroughs, evolving regulatory requirements, and growing expectations from patients are changing how therapies are developed and brought to market. For pharmaceutical, biotechnology, and medical technology companies, navigating this complexity requires more than scientific expertise. It demands informed strategic decisions, rigorous evidence, and a clear understanding of patient needs.

Alira Health supports life sciences companies and investors through strategic advisory, clinical research, real-world evidence, and patient engagement. With operations across North America, Europe, and Asia, the company brings together specialized capabilities to help clients navigate the scientific and commercial challenges of healthcare innovation.

Its consulting services span corporate and portfolio strategy, transaction advisory, regulatory strategy, market access, health economics and outcomes research, and commercialization. Its clinical research capabilities include clinical operations, biometrics, and pharmacovigilance. Across these areas, Alira Health emphasizes direct access to senior professionals whose experience and judgment help clients address complex challenges and make consequential decisions.



A distinguishing strength is Alira Health's commitment to understanding patients as active participants in healthcare innovation. Through direct relationships with patient communities, proprietary registries, and patient engagement programs, the company generates insights into how people experience disease, navigate treatment, and manage their health. These perspectives can inform clinical trial design, patient recruitment, evidence generation, and commercial strategy.

Digital platforms, including Health Storylines™ and SpherePX™, extend this work by supporting patient engagement and the collection of information about health experiences outside traditional clinical settings. Together with the company's real-world evidence capabilities, these resources help life sciences organizations better understand patient needs and the value of therapies in everyday practice.

As healthcare becomes increasingly data-driven, the challenge for life sciences companies is not simply accessing more information but

Alira Health: Bringing Patient Understanding to Healthcare Innovation

interpreting it effectively. Alira Health combines analytical capabilities, specialized data, and practical industry experience to help clients evaluate opportunities, navigate uncertainty, and translate evidence into action.

For Alira Health, the connection between scientific progress and patient experience is fundamental. By bringing these perspectives into the development and commercialization of healthcare innovations, the company pursues its mission to improve the lives of patients globally.



WALL ST
NEW YORK
MAGAZINE

BioMEMS Diagnostics: Revolutionizing Healthcare Through Portable Diagnostic Technology

As healthcare continues to evolve toward faster, more accessible, and personalized medical solutions, BioMEMS Diagnostics is developing an innovative technology platform designed to transform how medical testing is performed. Headquartered in Bloomfield Hills, Michigan, the company is working to bring sophisticated laboratory-style diagnostic capabilities directly to patients, healthcare providers, and professionals operating outside traditional laboratory environments.

Founded in April 2022, BioMEMS Diagnostics is pursuing a mission built around a straightforward principle: "The closer to the patient, the better the outcome." By combining advanced biosensor technology, portable analytical equipment, and digital connectivity, the company aims to eliminate many of the logistical barriers associated with conventional diagnostic testing.

A New Generation of Diagnostic Technology
Traditional laboratory testing often requires specialized equipment, trained personnel, sample transportation, and significant processing time. While conventional rapid tests offer greater convenience, many provide only limited diagnostic information.

BioMEMS Diagnostics is developing a solution intended to bridge this technological gap. At the center of its platform is a patent-pending biosensor chip integrated into a compact, single-use cartridge. The chip contains twelve testing wells, each capable of accommodating different diagnostic chemistry. Unlike technologies that require entirely different chips for different tests, BioMEMS has designed a standardized sensor architecture that can support multiple applications.

The company's envisioned system consists of three integrated components: a disposable diagnostic cartridge, a handheld analyzer, and a connected smartphone application. Together, these technologies are designed to enable users to collect a sample, conduct testing, and access digital results without requiring conventional laboratory infrastructure.

This standardized approach could offer important manufacturing advantages, allowing BioMEMS to expand its diagnostic capabilities while maintaining a consistent hardware platform.



New Frontier Labs

Advancing Innovative Treatments for Brown Recluse Spider Bites

New Frontier Labs is a biotechnology company focused on developing innovative medical treatments that address significant unmet healthcare needs. Our current research centers on a potentially groundbreaking approach to treating brown recluse spider bites by stopping inflammation before it progresses to severe tissue damage and necrosis.

Each year, an estimated 30,000 to 35,600 brown recluse spider bites occur in the United States. Despite the potentially serious consequences of these bites, there is currently no FDA-approved therapy specifically designed to prevent the associated tissue destruction. Existing medical care is largely focused on managing symptoms rather than preventing the underlying inflammatory processes that can lead to necrosis.

At New Frontier Labs, we believe that early intervention could fundamentally change how these injuries are treated.

Our investigational treatment utilizes diethyl azelate (DEA), a topical compound designed to address the early inflammatory stages following a spider bite. By targeting inflammation before irreversible tissue damage occurs, our goal is to develop an accessible, affordable, and effective therapeutic option for patients and healthcare providers.

Early exploratory research has produced encouraging findings. In a small, uncontrolled human study involving 14 participants, all 13 bites treated within four days reportedly resolved without adverse events. Additional research using a human skin model has demonstrated DEA's potential to protect against a variety of biological and chemical inflammatory challenges.

Although these preliminary results require further validation through controlled clinical studies, they provide an important foundation for continued development.

Our long-term vision extends beyond prescription drug development. Following regulatory approval, we intend to explore a practical first-aid topical treatment that could make early intervention more widely accessible. With projected product costs below $10 for a seven-day course, affordability is a central part of our development strategy.

To advance this program, New Frontier Labs is pursuing a $2.5 million staged funding initiative, beginning with a $500,000 milestone focused on securing orphan drug designation, followed by an additional $2 million to support development toward Investigational New Drug (IND) readiness.

Our ultimate objective is to bring this promising technology through the necessary regulatory and clinical development stages and establish strategic partnerships that can accelerate its commercialization.

At New Frontier Labs, we see scientific innovation as an opportunity to solve medical problems that have remained inadequately addressed for decades. By combining research, practical product development, and a commitment to affordability, we aim to transform a promising scientific discovery into a meaningful advancement in patient care.

Robert Streeper and Elzbieta Izbicka
New Frontier Labs

DEA remains investigational and is not FDA-approved. Its safety and efficacy have not been established through controlled clinical trials.

New Frontier Labs

Stopping inflammation before it becomes necrosis

An investigationaldrug,andlaterafirst-aidtopical,forearlyuseafterabrownreclusebite

NEED

Brownrecluse bites have no FDA-approved therapy, and the market is orphan-eligible (~30,000–35,600 US cases a year). Bites can be painful, and care today is largely symptomatic. Yet treatment is needed early, before inflammation drives necrosis.

PRODUCT

Topical DEA (diethyl azelate), applied early after a bite as a 7-day course, with cost of goods under $10. In an exploratory, uncontrolled human study (n=14), all 13 bites treated within 4 days resolved with no adverse events.


WHY IT MAY WORK

DEA is proposed to act at the early inflammatory steps, before necrosis. In a human skin model (~100 cytokines), DEA protected against diverse biological and chemical insults where NSAIDs and steroids did not. Its use for diseases associated with spider toxin and for pain mitigation is patented, and an anti-inflammatory patent filing is due in Q4 2026.

EXIT STRATEGY

Drug approval comes first; the first-aid kit follows approval. We plan to license or sell the program after Phase I, or sooner if a partner engages earlier, such as at an efficacy readout or once the program is FDA-ready. Orphan designation, if granted, and a defined regulatory path make the asset easier for a partner to evaluate.

Risk summary: DEA is investigational and not FDA-approved; efficacy in vivo has not been shown, and human data are small (n=14) and uncontrolled. Orphan or other designations, FDA approval, patent issuance, funding, partnerships and any sale or license are not assured. Further capital is required, and later financing may dilute investors. The U.S. market is small, and development depends on CROs and key personnel. Any offering is a private placement of restricted, illiquid securities, and investors could lose their entire investment. Forward-looking statements may differ materially from actual results; review the full disclosures and offering documents. For a further disclosure of both the potential risks and benefits of this transaction, please request the Management Deck.



DEA is proposed to act at steps 1 and 2, before necrosis.

STAGED FUNDING · $2.5M

MILESTONE 1 · 6 MONTHS

$0.5M

Secureorphandrug designation

MILESTONE2 · 24 MONTHS

+ $2M

ReachINDreadiness

WALL ST
NEW YORK
MAGAZINE



WALL ST
NEW YORK
MAGAZINE